Chapter 1: Clinical Exercise Physiology and Exercise Medicine

Chapter Introduction

The Lion has run alongside you a long way.

In K-12 you met your body in motion. At Associates you went into exercise physiology proper — sliding filament theory, the four energy systems, satellite cells and Schoenfeld's three-factor hypertrophy framework, the Fick equation and VO2 max, programming principles, the RED-S surface in survey. At Bachelor's you went molecular, cardiac, and clinical — the mTORC1 cascade from mechanical load through Rheb-GTP to S6K1 phosphorylation, the AMPK/PGC-1α/SIRT1 endurance signaling and the concurrent-training interference effect, cardiac adaptation at structural and molecular level, the athlete's heart versus hypertrophic cardiomyopathy differential at Maron and Pelliccia depth, exercise neuroscience at BDNF and hippocampal neurogenesis depth, RED-S at Loucks energy-availability and IOC 2018 consensus depth, exercise immunology, overtraining syndrome neuroendocrinology, and exercise research methods including the PED surface descriptively.

This chapter is the fourth step of the upper-division spiral.

At the Master's level, Coach Move goes translational. The molecular and cardiac physiology you learned at Bachelor's is the substrate of this chapter, not its content. What this chapter asks is the next question: given what we know about how exercise works at the molecular and cardiac level, what does clinical exercise physiology actually do for chronic-disease populations, what does sports medicine look like at clinical practice depth, what does population-level dose-response research tell us, what does the bench-to-bedside translation in exercise medicine actually achieve, and what does the PED research landscape look like at harms-epidemiology depth? This is the graduate question for movement specifically. Exercise medicine is one of the more rapidly evolving clinical-translational fields, with substantial successes (cardiac rehabilitation mortality reduction, exercise oncology guideline change, the Pedersen-Saltin exercise-as-medicine framework) and substantial methodological constraints (blinding impossibility, control-condition difficulty, adherence measurement, the publication-bias picture in sports science). The graduate-level student becomes able to read this landscape as the active translational landscape it is.

The voice is the same Lion. Capable. Confident. Full-power. Direct. What changes again is the depth. At Master's you are reading the primary clinical trials, the practice guidelines, the systematic reviews and meta-analyses, the population-cohort findings, the failed and successful translational programs, and the harms-epidemiology evidence that constitutes the actual record of contemporary exercise medicine.

A word about what this chapter is not, before you begin. This chapter is not a clinical-prescribing manual. Cardiac rehabilitation, exercise oncology prescription, diabetes-management training prescription, sports injury management, return-to-play decisions, and the broader landscape of clinical exercise prescription are real, well-researched, and present in these pages at clinical translational depth. They are not framed as protocols for you to prescribe in yourself or in others, and the chapter's treatment of training stimulus, intensity targets, and clinical decision-making is descriptive of the research and clinical practice — not a personal prescription. The clinical work of exercise medicine is the work of trained clinical exercise physiologists, athletic trainers, physical therapists, sports medicine physicians, cardiologists, oncologists, and the multidisciplinary teams within which they operate. The graduate-trained adjacent practitioner becomes able to read the literature and engage with clinical colleagues — never to substitute for clinical training.

A word about being a master's-level student in exercise-related fields, before you begin. This audience reads the chapter from a different position than the Bachelor's audience did. Some of you are training to be clinical exercise physiologists, athletic trainers, physical therapists, sports nutritionists, cardiac rehabilitation specialists, or exercise oncologists. Some of you are physicians, physical therapists, or athletic trainers returning for clinical-translational specialization. The chapter is written for that audience. The framing throughout remains recognition, clinical reasoning, and methodological depth — never prescriptive protocols. The actual clinical exercise prescription is the work of credentialed and licensed disciplines operating within established clinical relationships and within scope of practice.

A word about RED-S and eating disorders, before you begin. The bidirectional relationship between athletic populations and eating disorder risk is one of the more robust findings in clinical sports medicine. Master's-level training in exercise science, athletic training, dietetics, and pre-clinical sports medicine carries elevated eating-disorder prevalence in the student population itself, and the clinical populations these students will serve carry elevated prevalence as well. The chapter handles the clinical content carefully. If anything in the chapter — about body composition assessment, about energy availability, about training load and recovery — touches your own experience and you are working through it alone when you do not need to be, the verified crisis resources at the end of this chapter are real. Your program's counseling resources are real. The Lion is in your corner.

A word about performance-enhancing drugs, before you begin. The PED surface is treated at Master's depth as a harms-epidemiology surface: what does the long-term-outcome research actually show about the cardiac, psychiatric, and mortality consequences of non-medical anabolic-androgenic steroid use in athletes? The Bachelor's chapter acknowledged the PED surface descriptively; the Master's chapter goes into the actual outcome literature. The framing is honest about harms without normalizing the practice, and explicitly distinguishes the scientific literature on PED use from the scientific literature on gender-affirming hormone therapy — two distinct clinical and research domains that share some pharmacological substrates but address fundamentally different clinical questions. The chapter makes this distinction explicitly to prevent conflation, which has been a recurring problem in lay-press coverage.

This chapter has five lessons.

Lesson 1 is Clinical Exercise Physiology and Exercise-as-Medicine — exercise in cardiac rehabilitation at AACVPR clinical practice depth (the post-MI mortality reduction cohort literature, the supervised versus home-based comparison), exercise oncology at Schmitz / Campbell 2019 ACSM roundtable depth (the practice-changing guidance for exercise during and after cancer treatment), exercise for T2DM at Boulé 2001 JAMA HbA1c-meta-analysis depth and the Look AHEAD trial findings (the lateral connection to Coach Food Master's Lesson 3 on clinical nutrition specializations), and exercise for depression at Schuch 2016 / Cooney 2013 / Blumenthal SMILE trial depth (the lateral connection to Coach Brain Master's Lesson 1 on the depression treatment landscape).

Lesson 2 is Sports Medicine at Clinical Practice Depth — orthopedic injury at clinical depth (ACL tears and the KANON trial surgical-versus-conservative-management evidence base, rotator cuff pathology and treatment), concussion and chronic traumatic encephalopathy (CTE) at McKee, Omalu, and Boston University CTE Center research depth (the limits of current diagnostic methods — CTE is currently definitively diagnosed only post-mortem — the youth football controversy honestly framed), second-impact syndrome pathophysiology, stress fractures and overuse injury at the RED-S clinical intersection (cross-reference to Move Bachelor's Lesson 4), and tendinopathy at modern understanding depth (the shift from "tendinitis" to "tendinopathy" reflecting the actual pathology, the Alfredson and Cook eccentric loading research).

Lesson 3 is Exercise Epidemiology and Dose-Response Research — the physical activity guidelines lineage at graduate depth (1995 ACSM/CDC consensus, 2008 PAGAC, 2018 PAGAC report), the dose-response curve at population-level data depth (Lee et al. 2014 Lancet mortality data, Arem et al. 2015 JAMA Internal Medicine showing 3–5× recommended PA had highest mortality reduction with no J-curve harm signal in the studied range), the methodological problems in exercise epidemiology (self-reported versus accelerometer measurement, residual confounding, the reverse causation issue), sedentary behavior research as adjacent literature (Dunstan and Owen on sitting time as independent risk factor from physical activity), and Morris et al. 1953 Lancet London bus drivers study as foundational anchor.

Lesson 4 is Translational Exercise Research and the Bench-to-Bedside Pipeline — the NIH MoTrPAC initiative at translational research depth (the Molecular Transducers of Physical Activity Consortium mapping molecular responses to exercise across tissues), the exercise-as-polypharmacy framing (Pedersen and Saltin 2015 Scandinavian Journal of Medicine & Science in Sports "exercise is medicine for 26 chronic diseases"), the exercise-mimetic research direction (Evans PPARδ work, the irisin story and its controversies), the methodological difficulty of exercise intervention trials (control condition problem, blinding impossibility, adherence measurement, supervised versus home-based protocols), and the publication-bias picture in sports science research. Cross-references to Food Master's Lesson 5 and Brain Master's Lesson 5 on the broader translational-research methodology parallel.

Lesson 5 is Exercise Intervention Research Methods and the PED Harms-Epidemiology Landscape — exercise intervention trial design at clinical research methodology depth, the PED research literature at harms-epidemiology depth (Baggish et al. 2017 Circulation imaging studies showing systolic dysfunction in long-term AAS users, Pope's psychiatric morbidity research, the Frati 2014 cardiac mortality follow-up in former competitive bodybuilders and powerlifters, the AAS-associated suicide research), the wellness-industry "natural testosterone-boosting" claims evaluated against actual AAS pharmacology using the five-point framework, and the gender-affirming hormone therapy versus PED use scientific distinction named honestly.

The Lion is in no hurry. Begin.

---

Lesson 1: Clinical Exercise Physiology and Exercise-as-Medicine

Learning Objectives

By the end of this lesson, you will be able to:

• Describe contemporary cardiac rehabilitation at clinical practice depth, citing the AACVPR framework and the published cohort evidence for post-MI mortality reduction
• Describe the Schmitz et al. and Campbell et al. 2019 ACSM roundtable framework for exercise during and after cancer treatment, articulating why the 2019 framework was practice-changing relative to prior guidance
• Apply the Boulé et al. 2001 JAMA meta-analytic framework on exercise and HbA1c in T2DM, and integrate it with the Look AHEAD trial findings on lifestyle intervention in diabetes
• Describe the contemporary research base on exercise for depression (Schuch 2016, Cooney 2013, Blumenthal SMILE trials) at intervention-trial depth, and articulate where exercise sits in the depression treatment landscape relative to pharmacotherapy and CBT
• Articulate the role of exercise in the broader clinical-translational medicine landscape as a non-prescriptive description of what the research has established

Key Terms

Why Exercise-as-Medicine at Master's

A graduate-level chapter on exercise medicine does not begin with the most-discussed training methodology of the moment. It begins with the clinical translation — what does exercise actually do for the chronic-disease populations the master's-trained clinical exercise physiologist will serve, what is the evidence base for the specific prescriptions, and what are the implementation barriers that separate guideline from real-world practice? The contemporary exercise-as-medicine landscape is substantial: cardiac rehabilitation has a four-decade evidence base with documented mortality reduction; exercise oncology has produced practice-changing guidelines over the past 15 years; exercise for T2DM is now a first-line component of diabetes management across major guidelines; and the exercise-for-depression literature has matured to the point that exercise sits alongside pharmacotherapy and psychotherapy in the depression treatment landscape. The graduate-trained practitioner reads this landscape because it is the operational reality within which clinical exercise prescription occurs.

Cardiac Rehabilitation: The Foundational Clinical Translation

Cardiac rehabilitation is the original clinical exercise-as-medicine translation. The framework — structured supervised exercise, risk-factor modification, education, and behavioral support delivered over 8–12 weeks following a qualifying cardiac event — has been formalized since the 1970s and has accumulated one of the strongest evidence bases in clinical exercise medicine [1].

The AACVPR framework, most recently codified in the 6th edition of the AACVPR Guidelines for Cardiac Rehabilitation Programs and parallel American Heart Association / American College of Cardiology guidance [2][3], establishes the contemporary clinical structure: comprehensive risk assessment at program entry, individualized exercise prescription progressing from supervised facility-based sessions to home-based maintenance, integrated risk-factor modification (lipid management, blood pressure, glycemic control, smoking cessation, weight management, dietary counseling, psychosocial support), and structured progression toward long-term physical-activity maintenance. The clinical eligibility categories include post-myocardial infarction, post-coronary revascularization (PCI or CABG), stable angina, heart failure with reduced ejection fraction, and post-cardiac-transplantation, with expanded indications under continued discussion.

The mortality-reduction evidence for cardiac rehabilitation has accumulated steadily. The Anderson et al. 2016 Cochrane systematic review of 63 RCTs in 14,486 patients reported cardiac-rehabilitation-associated reductions in cardiovascular mortality (approximately 26% relative risk reduction) and hospital readmission, with effect sizes that have remained meaningful across decades of trials [4]. Observational registry studies in U.S. and European populations have reported similar magnitudes [5][6]. The Lancet Cardiology Commission on cardiac rehabilitation participation [7] characterized the implementation gap: despite the evidence, U.S. participation rates among eligible patients are approximately 20–30%, with substantial demographic disparities (lower participation in older, lower-income, Black, Hispanic, and rural patients).

The mechanisms of cardiac rehabilitation benefit are multifactorial. Direct training effects (improved peak VO2, reduced submaximal heart rate, lactate threshold elevation, plasma volume expansion — the integrated Fick-equation adaptations from Move Bachelor's Lesson 2) contribute. Indirect effects from risk-factor modification (LDL cholesterol reduction, blood pressure reduction, HbA1c improvement, smoking cessation, weight management) contribute. Psychosocial effects (reduced depression and anxiety, social engagement) contribute. The contemporary framing treats cardiac rehabilitation as a multimodal intervention with effects across each of these channels, with the integrated effect substantially larger than any single component would predict.

The contemporary translational research in cardiac rehabilitation includes work on home-based and hybrid delivery (Thomas et al. 2019 home-based CR feasibility trials extending access to populations for whom facility-based programs are impractical) [8], on the specific exercise prescription for heart failure populations (HF-ACTION trial findings on supervised exercise in HFrEF) [9], and on the broader question of which patients benefit most and which are at residual risk despite full program participation [10].

Exercise Oncology and the Campbell 2019 ACSM Roundtable

Exercise oncology has emerged as one of the most-rapidly-developing exercise-as-medicine sub-specialties. The clinical question — what exercise prescription is appropriate for patients during active cancer treatment and after treatment completion, across the diverse cancer types and treatment regimens — has been addressed through a substantial intervention-research literature accumulated since the 1990s.

The foundational synthesis was the 2010 ACSM Roundtable on Exercise Guidelines for Cancer Survivors (Schmitz et al., Medicine & Science in Sports & Exercise) [11]. The 2010 statement reviewed the available evidence at that point and articulated cancer-specific exercise prescription frameworks for breast, prostate, colon, hematologic, and gynecologic cancers, with the framing that exercise was safe and beneficial for most cancer survivors and should be incorporated into supportive-care planning.

The 2019 update (Campbell et al., Medicine & Science in Sports & Exercise) [12] was practice-changing. The 2019 multi-society consensus, drawing on the substantial intervention-trial literature accumulated since 2010, established that exercise prescription was appropriate during active cancer treatment (not only after) for specific defined outcomes: cancer-related fatigue, anxiety, depression, physical function, health-related quality of life, lymphedema. The recommended prescription — moderate-intensity aerobic exercise at least three times per week for at least 30 minutes per session, plus resistance training at least twice per week — was specified at clinical depth with adaptations for treatment-related side effects, fatigue, and cancer-specific contraindications. The framework explicitly addressed prehabilitation (exercise before surgery to optimize physiological reserve) as well as intra-treatment and post-treatment prescription.

The Schmitz laboratory body of work has been central to the field's development. The PAL (Physical Activity and Lymphedema) trial demonstrated that progressive resistance training in breast cancer survivors with lymphedema was safe and beneficial, reversing the prior clinical concern that resistance training would worsen the condition [13]. The work has shaped breast cancer survivorship care substantially.

The specific cancer findings include several that have entered clinical translation. Breast cancer: exercise during chemotherapy improves treatment tolerance, fatigue, physical function, and quality of life; resistance training is safe and beneficial in lymphedema populations; longitudinal exercise post-diagnosis is associated with reduced cancer-specific and all-cause mortality (Holmes et al. 2005 JAMA; Friedenreich et al. 2016) [14][15]. Prostate cancer: exercise during androgen deprivation therapy attenuates the muscle and bone loss associated with treatment (Galvão and colleagues' work) [16]. Colorectal cancer: physical activity post-diagnosis is associated with reduced recurrence and mortality (Meyerhardt et al. 2006 JCO) [17]. Hematologic malignancies: exercise during chemotherapy improves fatigue and function with appropriate safety considerations for cytopenias [18].

The CHALLENGE trial (Courneya et al. 2024 NEJM) provides one of the more recent practice-relevant pieces of evidence: a randomized controlled trial of structured exercise versus health-education control in 889 colon cancer survivors after adjuvant chemotherapy, demonstrating that the exercise intervention reduced cancer recurrence and improved overall survival over a median 7.9 years of follow-up [19]. The trial is the strongest current evidence for exercise's contribution to cancer-specific outcomes beyond symptom management.

The implementation gap in exercise oncology remains substantial. Despite the 2019 ACSM framework and parallel guidance from the American Cancer Society and the National Comprehensive Cancer Network, routine exercise prescription within oncology care remains uneven. Specialized exercise oncology programs exist principally at major academic cancer centers; community-practice integration is at an earlier stage. The graduate-trained clinical exercise physiologist who can deliver exercise oncology services within multidisciplinary cancer care addresses a real and persistent unmet need.

The lateral cross-reference to Coach Food Master's Lesson 3 on clinical nutrition specializations is direct. The exercise-oncology and nutrition-oncology literatures intersect at the cancer-cachexia population (covered in Food Master's at clinical depth), at the peri-operative ERAS (Enhanced Recovery After Surgery) framework that integrates pre-habilitation exercise with peri-operative nutrition optimization, and at the broader survivorship-care framework that integrates exercise and dietary intervention for cancer-specific outcomes.

Exercise for Type 2 Diabetes: The Boulé Meta-Analysis and Look AHEAD

Exercise for T2DM is now a first-line component of diabetes management across major clinical practice guidelines including the American Diabetes Association Standards of Care [20] and the European Association for the Study of Diabetes guidelines. The foundational synthesis is the Boulé et al. 2001 JAMA meta-analysis of structured exercise interventions in T2DM [21], which is one of the most-cited clinical-exercise-physiology papers and a strong foundational anchor for the broader exercise-as-medicine framework.

Boulé and colleagues synthesized 14 RCTs of structured exercise (aerobic or resistance) in T2DM, totaling 504 patients. The meta-analytic finding: structured exercise produced HbA1c reductions of approximately 0.66 percentage points compared to control, an effect size comparable to the magnitude of effect produced by adding an oral antidiabetic medication to existing treatment. The finding was striking at the time (and remains so): a non-pharmacological intervention producing pharmacological-magnitude glycemic improvement in T2DM, with the broader cardiovascular, body-composition, and quality-of-life benefits that exercise produces in addition to glycemia.

Subsequent meta-analytic work has extended the framework. The Umpierre et al. 2011 JAMA meta-analysis extended the analysis to combined aerobic-and-resistance training, reporting larger HbA1c reductions (approximately 0.89 percentage points) with combined modalities than with either modality alone [22]. The Pan et al. 2018 Diabetes Care meta-analysis updated the dose-response framework, identifying that moderate-intensity continuous training, high-intensity interval training, and resistance training all produced clinically meaningful glycemic improvement, with combined training producing the largest effects [23]. The contemporary clinical translation is that structured exercise — typically prescribed as approximately 150 minutes per week of moderate-intensity aerobic exercise plus 2–3 sessions per week of resistance training, with progression as tolerance permits — is a guideline-supported first-line intervention for glycemic management in T2DM.

The Look AHEAD trial (Wing and the Look AHEAD Research Group, 2013 NEJM) [24] tested intensive lifestyle intervention combining caloric restriction and increased physical activity against standardized diabetes support and education in 5,145 adults with T2DM and overweight or obesity. The trial findings — covered at depth in Coach Food Master's Lesson 5 — included substantial improvements in weight, fitness, glycemic control, sleep apnea, urinary incontinence, depression, and quality of life in the intensive-lifestyle arm, alongside the null primary result on cardiovascular events. The trial's interpretation has been complex (as discussed in Food Master's at translational research depth), but the demonstration that intensive lifestyle intervention produces multiple clinically meaningful benefits in T2DM has been a substantial contribution to the field.

The practical clinical translation in T2DM exercise prescription is delivered by a combination of certified diabetes care and education specialists, clinical exercise physiologists, and primary care teams. The progression from sedentary baseline to guideline-supported activity levels requires sustained behavioral support; the long-term adherence pattern shows substantial attenuation over years to decades. The graduate-trained practitioner familiar with the diabetes-exercise evidence base can engage informedly with diabetes care teams about exercise prescription within the patient's broader care plan.

Exercise for Depression: Where It Sits in the Treatment Landscape

The exercise-for-depression literature has matured substantially over the past two decades and now occupies a defined position in the depression treatment landscape. The field's principal meta-analytic synthesis is Schuch et al. 2016 Journal of Psychiatric Research [25], which extended prior reviews (including the controversial Cooney 2013 Cochrane review that had questioned the magnitude of exercise's antidepressant effect) by addressing several methodological concerns of earlier syntheses.

Schuch and colleagues synthesized RCTs of exercise interventions for major depressive disorder, applying restrictions to address methodological quality and publication bias. The principal finding: exercise produced large antidepressant effects (Cohen's d = 1.11 with conventional analysis; d = 0.66 after restricting to trials with low risk of bias; even stronger effects in higher-intensity protocols). The magnitude is comparable to or larger than typical effect sizes for first-line antidepressants in depression RCTs (which run approximately d = 0.30–0.50 across pharmaceutical trials when corrected for publication bias per Turner 2008 from Brain Master's Lesson 5).

The Cooney 2013 Cochrane review [26] had earlier reported substantially smaller effects, with the principal disagreement centered on study selection and quality-restriction criteria. The methodological discussion between the two literatures (Schuch and colleagues responding in detail to the Cochrane methodology, the Cochrane review's reanalysis under updated frameworks) has illuminated how meta-analytic choices substantially shape the apparent magnitude of an intervention's effect — a recurring theme across this Master's tier in nutrition, sleep medicine, and neuroscience literatures as well.

The SMILE trials (Standard Medical Intervention and Long-term Exercise) led by James Blumenthal at Duke have been the field's principal RCT contribution. SMILE-I (Blumenthal et al. 1999 Archives of Internal Medicine) compared aerobic exercise, sertraline, and combination treatment in 156 older adults with major depression and found broadly comparable response rates across the three conditions at 16 weeks [27]. SMILE-II (Blumenthal et al. 2007 Psychosomatic Medicine) extended the comparison to 202 adults across age range with similar findings [28]. The Blumenthal program has produced one of the cleaner translational stories: structured aerobic exercise produces clinically meaningful antidepressant response in depressed adults, with effect magnitude comparable to first-line pharmacotherapy in head-to-head trials.

The lateral cross-reference to Coach Brain Master's Lesson 1 on the depression treatment landscape is direct. Brain Master's Lesson 1 covered the depression treatment landscape from the pharmacology and neurostimulation angle — SSRIs, SNRIs, atypical antidepressants, the ketamine paradigm shift, psilocybin research, ECT, rTMS, DBS. Exercise sits within this landscape as one modality with effect sizes comparable to first-line medications and with the additional benefits that pharmacotherapy alone cannot deliver (cardiovascular, metabolic, musculoskeletal, sleep, social engagement). The contemporary clinical-translation framing is that exercise should be considered as a first-line treatment option for mild-to-moderate depression and as an adjunct in moderate-to-severe depression, alongside pharmacotherapy, psychotherapy, and other treatments. The implementation challenge is the same as the broader exercise-as-medicine pattern: the evidence supports the intervention, the prescription requires structured delivery with behavioral support, and routine clinical practice falls substantially short of what the evidence would support.

The mechanistic landscape for exercise's antidepressant effects connects to the Move Bachelor's Lesson 3 BDNF cascade — increased peripheral and central BDNF with exercise, increased adult hippocampal neurogenesis in animal models and human imaging studies, modulation of inflammatory cytokines, modulation of HPA reactivity, and the integrated effects on neuroplasticity-relevant signaling. The convergence with the inflammatory hypothesis of depression (Brain Master's Lesson 4) is direct: exercise reduces systemic inflammation through multiple mechanisms, contributing to antidepressant effects through the same pathway that anti-inflammatory pharmacological intervention (the Raison 2013 etanercept TRD framework) operates on.

What This Lesson Built

The clinical exercise-as-medicine landscape this lesson surveyed is the operational reality of contemporary clinical exercise physiology practice. The master's-level student should leave able to read a clinical exercise medicine trial with attention to design, comparator, effect size, implementation feasibility, and position in the broader treatment landscape for the target condition. The student should be able to articulate cardiac rehabilitation's mortality-reduction evidence base, the 2019 ACSM exercise oncology framework, the Boulé and Look AHEAD T2DM evidence, and the position of exercise in the depression treatment landscape — each at intervention-research depth.

This lesson is not a clinical-prescribing manual. It is a description of the field's current evidence base. The actual prescription of cardiac rehabilitation exercise, the implementation of cancer-specific exercise prescription, the diabetes exercise prescription, and the depression exercise prescription are the work of credentialed clinicians and certified clinical exercise physiologists operating within established clinical relationships and scopes of practice.

Lesson Check

1. Describe the AACVPR cardiac rehabilitation framework and articulate the magnitude of mortality reduction associated with cardiac rehabilitation participation per the Anderson 2016 Cochrane synthesis. What is the principal implementation gap, and what does it look like in U.S. participation patterns?
2. Summarize the Campbell et al. 2019 ACSM Roundtable framework for exercise during and after cancer treatment. Why was the 2019 framework practice-changing relative to the 2010 framework?
3. State the principal finding of the Boulé et al. 2001 JAMA meta-analysis on exercise and HbA1c in T2DM. How does the magnitude compare to pharmacological glycemic intervention, and what does the comparison establish about exercise as first-line diabetes management?
4. Compare the Schuch 2016 and Cooney 2013 meta-analyses on exercise for depression. What accounts for the difference in reported effect sizes, and what is the contemporary working framing of exercise's position in the depression treatment landscape?
5. Articulate the lateral connection between Move Master's Lesson 1 (exercise for depression) and Brain Master's Lesson 1 (depression treatment landscape). How does exercise fit alongside pharmacotherapy, psychotherapy, and neurostimulation interventions in the broader treatment picture?

---

Lesson 2: Sports Medicine at Clinical Practice Depth

Learning Objectives

By the end of this lesson, you will be able to:

• Describe ACL injury treatment at clinical practice depth, articulating the KANON trial findings on surgical versus conservative management, and identify the contemporary translational picture for ACL reconstruction decision-making
• Describe rotator cuff pathology at clinical practice depth (the impingement framework, partial- and full-thickness tears, the surgical-versus-conservative-management evidence base)
• Articulate the concussion and chronic traumatic encephalopathy (CTE) research landscape honestly at McKee / Omalu / Boston University CTE Center depth, identify the limits of current diagnostic methods (definitive diagnosis remains post-mortem), and engage with the youth football controversy as the unresolved research and policy question it is
• Describe second-impact syndrome pathophysiology and articulate the return-to-play decision framework in concussion management
• Describe contemporary tendinopathy understanding (the shift from "tendinitis" to "tendinopathy" reflecting actual pathology) and the Alfredson and Cook eccentric loading research evidence base

Key Terms

Why Sports Medicine at Master's

Sports medicine is the clinical sub-specialty within which a substantial fraction of master's-trained exercise physiologists, athletic trainers, and physical therapists practice. The contemporary sports medicine landscape integrates orthopedic surgery, primary care sports medicine, physical medicine and rehabilitation, athletic training, physical therapy, and adjacent disciplines into multidisciplinary care of athletic populations and active patients across the lifespan. The graduate-trained adjacent practitioner who is fluent in the contemporary clinical evidence base for the major sports medicine conditions — orthopedic injury, concussion and TBI, RED-S and overuse injury, tendinopathy — engages with the field's clinical work informedly and at appropriate scope.

ACL Injury: The KANON Trial and the Surgical-Conservative Debate

Anterior cruciate ligament tears are among the most clinically and economically significant athletic injuries in modern medicine. Estimated U.S. incidence is approximately 200,000–250,000 per year, with reconstruction rates of approximately 60–70% in the higher-activity-level populations [29]. The clinical decision-making about reconstruction has been substantially shaped by the KANON trial (Knee Anterior cruciate ligament, NON-surgical versus surgical treatment) led by Frobell, Lohmander, and colleagues in Sweden [30][31].

The trial design: 121 young, active adults (mean age 26, all <35 years) with acute ACL injury were randomized to early ACL reconstruction plus structured rehabilitation versus structured rehabilitation alone with optional delayed reconstruction if knee instability persisted. The primary outcome was knee function on the KOOS (Knee injury and Osteoarthritis Outcome Score) at 2 years; longer-term follow-up extended to 5 years.

The principal findings: at 2 years (Frobell 2010 NEJM), the two strategies produced statistically similar mean KOOS scores. Approximately 39% of the rehabilitation-alone group eventually underwent delayed reconstruction; the remaining 61% achieved functional knee stability without surgery. At 5 years (Frobell 2013 NEJM), the two strategies remained statistically similar on the primary outcome.

The translational implications have been substantial and contested. The trial demonstrated that early ACL reconstruction is not categorically required for active young adults with ACL injury — a finding at odds with the dominant clinical practice pattern of routine surgical reconstruction. The interpretation has been varied. Some practitioners have framed the result as supporting a trial of rehabilitation before considering reconstruction; others have emphasized that the 39% requiring delayed reconstruction reflects an actual surgical need that early reconstruction would have addressed directly; others have emphasized that the KANON population (young, active, athletic) may not generalize to populations with higher demands for cutting-and-pivoting sport return.

The broader contemporary framework (van Yperen et al. 2018 American Journal of Sports Medicine update; the 2023 BJSM consensus on ACL management) has integrated KANON and adjacent evidence into a shared decision-making framework: ACL reconstruction is appropriate for many but not all patients; the decision incorporates the patient's activity goals, knee instability symptoms with rehabilitation, occupational demands, age, and concurrent injuries; rehabilitation is required regardless of whether reconstruction is performed [32][33]. The long-term osteoarthritis question (whether reconstruction prevents the post-traumatic osteoarthritis associated with ACL injury) remains an active area of investigation; available evidence suggests that reconstruction does not eliminate the elevated post-injury osteoarthritis risk [34].

The clinical reality of contemporary U.S. ACL practice is that reconstruction rates remain substantially higher than the KANON framework would suggest. The implementation gap reflects multiple factors: surgeon training and practice patterns, patient expectations (particularly in competitive athletic populations), the demand for rapid return-to-sport, and the longitudinal-outcome uncertainty that complicates the conservative-management trial. The graduate-trained adjacent practitioner can engage with patients and surgical colleagues about the evidence base for the decision without prescribing the decision itself.

Rotator Cuff Pathology and Treatment

Rotator cuff pathology spans a clinical spectrum from impingement and tendinopathy through partial-thickness tear through full-thickness tear with progressive functional consequences. The contemporary framework has substantially revised the historical understanding [35].

The subacromial impingement framework (Neer 1972 original) has been substantially revised over the past two decades, with current evidence supporting that the bone-on-tendon mechanical impingement model does not adequately account for the underlying pathology in most rotator cuff disease [36]. The contemporary understanding integrates intrinsic tendon degeneration, intratendinous loading, and altered scapulothoracic kinematics into a multifactorial framework that emphasizes the rotator cuff tendon-degeneration substrate as the primary pathology and the mechanical impingement as a secondary contributor in some patients.

The treatment evidence base has been substantially updated by the CSAW trial (Beard et al. 2018 Lancet) of arthroscopic subacromial decompression versus diagnostic arthroscopy versus no treatment in symptomatic subacromial pain syndrome [37]. CSAW found that arthroscopic subacromial decompression did not produce clinically meaningful pain improvement over diagnostic arthroscopy alone (a placebo-controlled surgical comparison), and both surgical conditions produced limited improvement over no-treatment control. The trial substantially constrained the role of surgical decompression for subacromial pain syndrome and shifted contemporary practice toward exercise-based rehabilitation as first-line treatment.

For partial-thickness and small full-thickness rotator cuff tears, contemporary evidence supports structured exercise rehabilitation as first-line treatment with surgical repair reserved for patients who fail rehabilitation, who have substantial functional limitation despite rehabilitation, or who have specific indications such as acute traumatic full-thickness tear in younger active patients [38]. The Kuhn et al. 2013 MOON Shoulder Group multicenter cohort study of nonoperative treatment for atraumatic full-thickness tears demonstrated that approximately 75% of patients achieved acceptable function at 2-year follow-up without surgery [39]. The clinical translation is increasingly conservative-first for most rotator cuff presentations, with surgical decision-making restricted to defined indications.

Concussion, Chronic Traumatic Encephalopathy, and the Honest Research Picture

The concussion and CTE landscape requires honest engagement at master's depth. The field has matured substantially over the past two decades from a clinical position of routine return-to-play within hours of concussion (the historical practice in many contact sports) to a contemporary position of structured concussion assessment, graduated return-to-play protocols, and substantial public-health concern about long-term consequences of repetitive head impacts.

The acute concussion management framework, codified in the Concussion in Sport Group (CISG) Consensus Statements (most recent: Patricios et al. 2023 British Journal of Sports Medicine) [40], integrates pre-season baseline assessment (SCAT-6 and adjuncts), acute sideline evaluation, structured return-to-school and return-to-play progressions, and persistent symptom management. The contemporary framing emphasizes that concussion is a clinical diagnosis (not imaging-defined), that recovery typically takes 1–4 weeks in adults and longer in adolescents, that physical and cognitive rest during the first 24–48 hours followed by graduated activity reintroduction supports recovery, and that persistent post-concussion symptoms warrant multidisciplinary management.

The chronic traumatic encephalopathy (CTE) picture is the field's most substantial honest engagement. CTE was originally described in boxers ("dementia pugilistica," Martland 1928), revived in modern clinical and pathological depth by Bennet Omalu's 2005 Neurosurgery report on a former NFL player [41], and substantially developed by Ann McKee and the Boston University CTE Center through systematic post-mortem examination of brain donors with substantial head-impact exposure histories [42][43]. The pathological hallmark — perivascular accumulation of hyperphosphorylated tau (p-tau) in a characteristic distribution at the depths of cortical sulci — distinguishes CTE from other tau-opathies and from incidental tau changes of aging.

The Boston University CTE Center cohort findings have been substantial and substantively important. The Mez et al. 2017 JAMA study reported CTE pathology in 99% of brains donated by deceased former NFL players (110 of 111) and 91% of college football players (48 of 53), establishing the pathology's prevalence in heavily-exposed populations [44]. The substantial caveat is selection bias: donor brains come from families with concern about cognitive or behavioral changes in the deceased; the studied population is not representative of all former players. The contemporary research direction is establishing population-level prevalence in unselected former-player cohorts and in matched comparison groups, work that is methodologically demanding and still maturing.

The diagnostic limit is structural and important. As of mid-2026, CTE is definitively diagnosed only by post-mortem neuropathological examination. The clinical syndrome associated with the pathology — referred to in research literature as Traumatic Encephalopathy Syndrome (TES, per the 2021 NINDS consensus criteria, Katz et al.) — is a clinical construct that does not require post-mortem confirmation but does not constitute definitive CTE diagnosis [45]. In vivo diagnostic biomarkers (tau PET imaging, CSF p-tau, blood-based biomarkers) are at active development stage but have not yet achieved validated diagnostic status comparable to AD biomarker frameworks. The clinical and lay-press conflation of "CTE diagnosed in life" with the actual post-mortem pathology is a recurring source of confusion that the master's-level practitioner can address informedly.

The youth football controversy is an active research and policy question. The cumulative-head-impact exposure framework — emphasizing that the primary risk factor for CTE pathology may be cumulative subconcussive impacts over years of play rather than the discrete diagnosed concussions — has shifted clinical and policy attention to youth and recreational players, where exposure begins in childhood and accumulates over decades. The Alosco et al. 2020 Annals of Neurology analysis reported associations between age of first exposure to American football and earlier cognitive and behavioral symptom onset in former players [46]. The contemporary policy translation has included rule changes in youth football, calls for delayed tackle introduction, and broader public-health attention to head-impact exposure across sports including soccer (heading), ice hockey, and combat sports. The graduate-trained practitioner engages with this material as the active research and policy landscape it is, holding the substantial pathological evidence with appropriate seriousness while recognizing the methodological constraints on the human-population epidemiological evidence.

Second-Impact Syndrome and Return-to-Play

Second-impact syndrome (SIS) is a rare but potentially catastrophic syndrome of cerebral edema and brain herniation occurring when a second head impact is sustained before symptoms from a first concussion have resolved. The mechanism is hypothesized to involve loss of cerebrovascular autoregulation in the post-concussion period such that the second impact precipitates rapid cerebral edema. The condition predominantly affects adolescents and is associated with substantial mortality and severe neurological morbidity when it occurs [47][48].

The clinical translation of SIS recognition has been to support strict return-to-play protocols: athletes with diagnosed concussion are removed from play and do not return to contact activity until symptom resolution and completion of a graduated return-to-play progression. The contemporary CISG framework codifies this principle, and most U.S. state-level concussion legislation (passed in all 50 states by approximately 2014) operationalizes the same principle. The clinical reality is that adherence to these frameworks remains imperfect, with under-reporting of concussion symptoms by athletes (particularly in competitive contexts) being a recurring problem.

Stress Fractures, Overuse Injury, and the RED-S Intersection

Stress fractures and overuse injuries in athletic populations are clinically and pathophysiologically connected to the energy availability framework covered in Move Bachelor's Lesson 4. The clinical pattern: chronic low energy availability (energy intake minus exercise energy expenditure normalized to fat-free mass below 30 kcal/kg FFM/day per the Loucks framework) produces hormonal dysregulation including reduced gonadotropin pulsatility, suppressed reproductive hormones, altered thyroid hormone metabolism, and altered IGF-1 and growth hormone signaling, with downstream consequences for bone mineral density and bone remodeling [49].

The clinical translation at sports medicine depth includes recognition that stress fractures in athletes — particularly in repeated, recurrent, or unusual sites — warrant evaluation for the energy availability and broader RED-S framework. The clinical workup integrates dietary intake history, training load history, menstrual function in female athletes (and equivalent hormonal indices in male athletes per the male athlete RED-S framework), bone density assessment, and broader endocrine evaluation. The clinical management is multidisciplinary, integrating sports dietetics, sports medicine, and where indicated reproductive endocrinology and psychiatric or psychological support.

The De Souza, Williams, and adjacent program work on female athlete reproductive function — covered at Bachelor's depth — extends at Master's level into the clinical-translational framework that is now operational in sports medicine practice. The IOC 2023 RED-S consensus update [50] provides the contemporary clinical framework, extending the 2018 consensus into more granular clinical-decision tools. The graduate-trained sports medicine practitioner familiar with this framework recognizes the stress-fracture-RED-S connection routinely and engages with the multidisciplinary care that the syndrome requires.

Tendinopathy: The Modern Pathological Framework

The contemporary understanding of chronic tendon pain has substantially revised the historical framework. The traditional "tendinitis" term implied an inflammatory pathology that the histological evidence does not support — chronic painful tendons show degenerative changes (disorganized collagen architecture, increased ground substance, neovascularization, altered cellular phenotype) without prominent inflammatory infiltrate [51]. The contemporary term tendinopathy reflects the actual pathology and has displaced "tendinitis" across the sports medicine literature, although the older term persists in lay usage.

The Alfredson and colleagues body of work on Achilles tendinopathy treatment has been foundational [52][53]. Alfredson's heavy-load eccentric calf exercise protocol (3 sets of 15 repetitions, twice daily, with progressive loading, performed for 12 weeks) produced substantial pain reduction and functional improvement in chronic mid-portion Achilles tendinopathy. The mechanistic framework — that eccentric loading produces specific tendon adaptations including collagen synthesis, neovascular regression, and altered nociceptive signaling — has been substantially supported in subsequent work, though the specific mechanism of clinical effect remains under active investigation.

The Jill Cook and Ebonie Rio framework has extended the tendinopathy understanding into a clinical-management model emphasizing the continuum from reactive tendinopathy through tendon dysrepair to degenerative tendinopathy, with stage-specific clinical implications and load-management approaches [54][55]. The contemporary clinical management of tendinopathy across the principal sites (Achilles, patellar, lateral elbow, rotator cuff, gluteal) typically integrates structured progressive loading (eccentric, isometric, heavy-slow-resistance, and progressive functional loading depending on stage and site), patient education about pain neuroscience, and time-course expectation-setting given that chronic tendinopathy typically requires months of structured loading to achieve resolution.

The less effective interventions for tendinopathy include: corticosteroid injection (short-term pain relief but worse long-term outcomes), eccentric loading without progression or loading volume adequate to produce adaptation, complete rest (which deconditions the tendon further), and the broader "stretch and ice" framework. The shift from these older approaches to evidence-supported progressive loading frameworks has been one of the cleaner clinical-translation stories in sports medicine.

What This Lesson Built

The sports medicine landscape this lesson surveyed is the operational reality of contemporary sports medicine clinical practice. The master's-level student should leave able to read a sports medicine clinical trial with appropriate methodological attention; engage with the major condition categories (ACL, rotator cuff, concussion, tendinopathy, RED-S) at clinical practice depth; and articulate the contemporary evidence-supported frameworks for each.

The CTE landscape deserves particular master's-level engagement. The pathological evidence is substantial; the population-level epidemiology is methodologically demanding and still maturing; the diagnostic limit (definitive diagnosis post-mortem) is important; the youth-football controversy is active. The graduate-trained adjacent practitioner who can engage with this material honestly contributes to the broader public-health conversation about head-impact exposure across sports.

Lesson Check

1. Describe the KANON trial design and 2- and 5-year findings on ACL reconstruction versus structured rehabilitation in young active adults. How has the trial shaped contemporary ACL management, and what is the principal implementation gap relative to the trial's findings?
2. Describe the CSAW trial findings on arthroscopic subacromial decompression for subacromial pain syndrome. How has the trial shaped contemporary management of subacromial pain and rotator cuff pathology?
3. Articulate the CTE diagnostic landscape honestly. What is the pathological definition, what is the contemporary diagnostic limit, what is the Boston University CTE Center cohort evidence, and what is the principal methodological caveat to that evidence?
4. Describe second-impact syndrome and articulate the clinical-translation logic that supports strict return-to-play protocols in concussion management.
5. Describe contemporary tendinopathy management at the level of: the pathological framework distinguishing tendinopathy from the older "tendinitis" concept, the Alfredson eccentric loading evidence base, and the Cook/Rio clinical-staging framework.

---

Lesson 3: Exercise Epidemiology and Dose-Response Research

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the Morris et al. 1953 Lancet London bus drivers study as the foundational exercise epidemiology paper and identify its specific methodological contributions to the field
• Trace the physical activity guidelines lineage from the 1995 ACSM/CDC consensus through the 2008 PAGAC report to the 2018 PAGAC Scientific Report at graduate depth
• Describe the dose-response evidence base at population-level data depth, citing Lee et al. 2014 Lancet and Arem et al. 2015 JAMA Internal Medicine, and articulate the absence of a J-curve harm signal in the studied physical activity range
• Identify the principal methodological problems in exercise epidemiology (self-reported versus accelerometer-measured activity, residual confounding, reverse causation) and articulate the methodological responses the field has developed
• Describe sedentary behavior research as adjacent epidemiological literature (Dunstan, Owen work on sitting time as independent risk factor)

Key Terms

Why Exercise Epidemiology at Master's

A graduate-level chapter on exercise medicine cannot proceed without the population-level translational frame. The clinical exercise-as-medicine framework of Lesson 1 and the sports medicine framework of Lesson 2 operate within a broader public-health translational landscape that has been substantially shaped by the exercise epidemiology research lineage. The contemporary U.S. and global physical activity guidelines — which inform clinical practice, school physical education policy, urban design, and workplace wellness frameworks — rest on a six-decade exercise epidemiology evidence base that the master's-trained practitioner needs to be able to engage with informedly.

This lesson's methodological structure parallels Coach Food Master's Lesson 1 on nutritional epidemiology and Coach Sleep Master's Lesson 3 on sleep epidemiology. The three lessons share substantial methodological territory — the structural challenges of measuring lifestyle exposures, the confounding-and-reverse-causation problem, the cohort-versus-RCT trade-offs, the population-level dose-response framework. The graduate student fluent across these three should be able to engage with any lifestyle-epidemiology literature at appropriate methodological depth.

Morris 1953: The Foundational Exercise Epidemiology Paper

The foundational anchor for this chapter sits in this lesson. In 1953, Jerry Morris and colleagues at the British Medical Research Council published in The Lancet a paper titled Coronary heart-disease and physical activity of work [56]. The paper compared coronary heart disease incidence between London double-decker bus drivers (who sat at the wheel during their shifts) and bus conductors (who climbed approximately 600 stairs per day collecting fares on the same buses). The conductors had approximately half the coronary heart disease incidence and mortality of the drivers despite occupying the same demographic, occupational, and socioeconomic context.

The paper is foundational for several reasons. First, it was the first rigorous population-level demonstration of the physical activity / cardiovascular health relationship. Prior to Morris, the relationship was suggested by anecdotal and small-sample observations; Morris established it at population epidemiological scale. Second, the comparison design (drivers versus conductors within the same bus company) substantially controlled for the broader social, demographic, and occupational confounders that typically complicate physical activity epidemiology. Third, the paper introduced the methodological framework of using occupational physical activity as exposure measurement, which influenced the subsequent decade of British and American exercise epidemiology. Fourth, the paper opened the substantial Morris research program that extended into the British Civil Service cohort, leisure-time physical activity assessment, and the eventual establishment of physical activity as a major modifiable cardiovascular risk factor [57][58].

A master's-level reader of the Morris paper at translational depth recognizes its specific methodological contributions and the structural limits of even an elegant occupational-comparison design. The drivers-versus-conductors comparison is robust against many obvious confounders but cannot rule out subtle selection effects (workers self-selecting into driving versus conducting based on health status), differential exposures beyond PA (driving stress, weight, dietary patterns differing between roles), and the broader generalizability question (occupational PA in 1950s London bus workers may not predict leisure-time PA effects in contemporary populations). The paper's lasting contribution is the methodological-and-conceptual foundation it laid for the field, not the quantitative magnitude of the specific comparison it reported.

The Physical Activity Guidelines Lineage

The contemporary physical activity guidelines reflect a six-decade synthesis of the exercise epidemiology evidence base, with progressively more formal scientific review processes shaping each iteration.

The 1995 ACSM/CDC consensus (Pate et al. JAMA) [59] was the first major coordinated U.S. statement recommending that adults should accumulate at least 30 minutes of moderate-intensity physical activity on most days of the week, with the framework that activity could be accumulated in 10-minute or longer bouts. The statement reflected the accumulating evidence that even moderate-intensity PA below the levels traditionally targeted for athletic conditioning produced meaningful cardiovascular and metabolic health benefits.

The 2008 Physical Activity Guidelines for Americans (PAGA) — the first formal federal physical activity guidelines, issued by HHS following systematic scientific review by the Physical Activity Guidelines Advisory Committee — established the contemporary structure: 150–300 minutes per week of moderate-intensity aerobic activity OR 75–150 minutes per week of vigorous-intensity activity (or equivalent combinations) PLUS muscle-strengthening activities involving major muscle groups on 2 or more days per week [60].

The 2018 PAGA update — the second federal guidelines, issued following the 2018 PAGAC Scientific Report — substantially extended the framework. The 2018 update eliminated the prior requirement that PA bouts be at least 10 minutes (recognizing that the evidence supported health benefits of even shorter bouts of activity), expanded the population-specific guidance (pregnant and postpartum women, older adults, people with chronic conditions and disabilities), added explicit guidance on reducing sedentary behavior, and emphasized that some PA is better than none with dose-response benefit continuing into very high activity levels [61][62].

The 2018 PAGAC Scientific Report itself is one of the more substantial systematic-review documents in lifestyle medicine [63]. The committee reviewed approximately 1,300 systematic reviews and meta-analyses across 25+ outcome categories (all-cause mortality, cardiovascular disease, cancer, type 2 diabetes, brain health and cognition, mental health, sleep, bone and muscle health, and many others), producing graded conclusions about the strength of evidence linking physical activity to each outcome. The report's conclusion was broadly that physical activity produces meaningful benefits across an exceptionally wide range of health outcomes, with the dose-response relationship continuing into activity levels substantially above the recommended minimums.

Dose-Response: Lee 2014 and Arem 2015

The contemporary dose-response framework for physical activity and mortality has been substantially shaped by two major pooled cohort analyses.

The Lee et al. 2012 Lancet analysis (sometimes cited as Lee 2014 for the related companion paper) [64] examined physical inactivity as a global health burden across 33 countries, concluding that physical inactivity caused approximately 5.3 million deaths globally per year — a magnitude comparable to that attributed to tobacco use and approaching the disease burden of obesity. The framework established physical inactivity as a population-health priority on the same scale as the major established risk factors.

The Arem et al. 2015 JAMA Internal Medicine pooled cohort analysis is the more methodologically rigorous treatment of the dose-response question [65]. The analysis pooled six prospective U.S. cohorts (NIH-AARP, ACS Cancer Prevention Study II Nutrition Cohort, NHS, NHSII, HPFS, BCDDP) for a total of 661,137 participants with 14.2 years of follow-up. Physical activity was assessed via self-report at multiple time points; mortality was ascertained via national death indices.

The principal findings: relative to no leisure-time MVPA, the dose-response curve showed substantial mortality reduction beginning at activity levels well below the recommended 150 min/week minimum (approximately 20% mortality reduction at 50–75% of recommended minimum); the recommended minimum (150 min/week) produced approximately 31% mortality reduction; 2–3× the recommended minimum produced approximately 37% mortality reduction; 3–5× the recommended minimum produced the largest reductions of approximately 39%. Critically, the curve did not show a J-curve harm signal across the studied range — activity levels exceeding 10× the recommended minimum did not produce mortality elevation, with the highest categories continuing to show benefit (though with diminishing returns at the upper end).

The translational implications have been substantial. The Arem framework supports several practice-relevant conclusions: any physical activity is better than none with substantial benefit beginning well below guideline minimums; meeting the guidelines produces meaningful additional benefit; substantially exceeding the guidelines produces further benefit with diminishing returns; the upper-end concern about excessive exercise mortality (the "U-shaped curve") is not supported by the available large-cohort data in the studied populations and activity ranges. The framework has been broadly stable across subsequent updates and replication in non-U.S. populations [66][67].

The caveat at master's depth is that the Arem framework rests on self-reported physical activity in U.S. cohort populations with characteristic measurement and selection structures. The accelerometer-measured activity literature (next discussion) has produced complementary but sometimes divergent dose-response patterns, and the very-high-activity range (e.g., elite endurance athletes accumulating 15+ hours per week of training) is not well-represented in standard cohort data and remains an area where the cardiac-risk surface (covered in Move Bachelor's Lesson 2) provides relevant additional context.

Methodological Problems: Measurement, Confounding, Reverse Causation

The exercise epidemiology literature faces several structural methodological constraints that the master's-level reader engages with explicitly.

Self-reported versus accelerometer-measured physical activity. Most published physical activity epidemiology, including the foundational Morris work and the Arem framework, rests on self-reported physical activity assessment (typically via questionnaire items asking about leisure-time activities, frequency, and duration). Self-report is inexpensive at scale but carries substantial measurement error: recall bias, social-desirability bias (over-reporting of valued behaviors), instrument limits (typical questionnaires miss substantial low-intensity ambulatory activity), and the systematic divergence of self-report from objectively measured activity (the typical correlation between self-reported MVPA and accelerometer-measured MVPA is approximately 0.3–0.4 — modest at population level) [68].

The accelerometer literature has expanded substantially as wrist- and waist-worn devices have become routine in research. The Strain et al. 2024 Lancet Public Health analysis of accelerometer-measured activity across multiple cohorts including UK Biobank reported dose-response findings that were broadly consistent with the self-reported literature in direction but produced somewhat different magnitude estimates and steeper benefit curves at the lower end of the activity range [69]. The Saint-Maurice et al. 2020 JAMA analysis of NHANES accelerometer data demonstrated that accelerometer-measured total daily steps were inversely associated with all-cause mortality with a continuous dose-response that did not plateau until approximately 7,500–10,000 steps per day in middle-aged adults [70]. The Paluch et al. 2022 Lancet Public Health meta-analysis of accelerometer-measured daily steps and mortality refined the dose-response framework across age groups [71].

The contemporary picture is that accelerometer and self-report literatures converge on qualitatively similar conclusions about dose-response direction and magnitude while differing in specific quantitative details. Master's-level engagement with either literature requires attention to which is being cited and what the measurement structure implies.

Residual confounding and the healthy user effect. Physically active people differ from less active people in many dimensions beyond physical activity itself — they are less likely to smoke, more likely to maintain healthier dietary patterns, more likely to maintain regular healthcare, more likely to have higher socioeconomic position and education, more likely to live in environments supportive of activity, and more likely to engage in a broader pattern of health-promoting behaviors. Statistical adjustment for measured confounders addresses some of this; residual confounding from unmeasured behaviors and exposures cannot be fully addressed in observational analysis.

The methodological response has paralleled the broader epidemiology adaptations covered in Food Master's Lesson 1: propensity-score methods to balance measured covariates between exposure groups, instrumental variables and Mendelian-randomization approaches where genetic instruments for physical activity are available, and triangulation across multiple study designs to identify findings robust to specific confounding structures.

Reverse causation. People with developing or established chronic disease typically reduce physical activity as a consequence of their disease, producing apparent associations between low PA and adverse outcomes that reflect disease-causing-low-PA rather than low-PA-causing-disease. The methodological response has included exclusion of participants with prevalent disease at baseline, exclusion of mortality and adverse events in the first 2–5 years of follow-up (when disease that produced low PA is more likely to cause death), and lagged exposure-outcome analysis frameworks. The contemporary major cohort analyses (Arem, Strain, Paluch) implement these methodological adaptations as standard.

Sedentary Behavior as Adjacent Literature

Sedentary behavior has emerged over the past 15 years as a distinct epidemiological exposure separate from physical inactivity. The conceptual distinction: physical inactivity is the failure to engage in sufficient MVPA; sedentary behavior is time spent in sitting, reclining, or lying postures at energy expenditures ≤1.5 METs while awake. A person can meet physical activity guidelines (engaging in 30+ minutes of MVPA daily) and still spend the remaining 15 waking hours sedentary; the two exposures are distinct.

The David Dunstan and Neville Owen research program at Australia's Baker Heart and Diabetes Institute (Dunstan) and the University of Queensland (Owen) has been foundational [72][73]. The AusDiab cohort analysis (Dunstan et al. 2010 Circulation) demonstrated that television viewing time was associated with cardiovascular and all-cause mortality independent of leisure-time physical activity [74]. Subsequent work has extended the framework to broader sedentary measures and to mechanistic intervention studies demonstrating that sedentary-period interruption (light-intensity activity breaks every 20–30 minutes) attenuates postprandial glucose and triglyceride responses in metabolic-laboratory studies [75][76].

The 2018 PAGAC and PAGA explicitly incorporated sedentary behavior into U.S. guidance, recommending reduction of sedentary time in addition to meeting MVPA recommendations. The contemporary clinical-translation framework treats physical activity and sedentary behavior as complementary modifiable behaviors rather than substitutes; reducing sedentary time is health-relevant even in individuals who meet MVPA guidelines.

The Stamatakis 2019 BMJ meta-analysis quantified the joint effect: high MVPA largely (but not entirely) attenuates the mortality risk associated with high sedentary time; very high MVPA in some analyses fully attenuates the sedentary-time risk [77]. The clinical and policy translation is that reducing sedentary time is a meaningful target alongside increasing MVPA, particularly for populations where increasing MVPA is difficult.

What This Lesson Built

The master's-level public-health-exercise student should leave this lesson with several capacities: the ability to read a physical activity epidemiology paper with attention to measurement instrument, confounding adjustment, and reverse-causation handling; the ability to engage with the U.S. and global physical activity guidelines as the product of a substantial systematic-review process; the ability to apply the dose-response framework (Arem, accelerometer literature) to clinical and population health communication; and the ability to integrate sedentary behavior as an adjacent exposure distinct from physical inactivity.

The lesson's methodological structure deserves emphasis as parallel to Food Master's Lesson 1 on nutritional epidemiology and Sleep Master's Lesson 3 on sleep epidemiology. The three lessons share substantial methodological territory; the graduate student fluent across them should recognize the common structural features of lifestyle epidemiology and engage with any new lifestyle-exposure literature at appropriate methodological depth.

Lesson Check

1. Describe the Morris et al. 1953 Lancet London bus drivers study at the level of design, comparison, finding, and methodological contributions to the foundational exercise epidemiology framework.
2. Trace the U.S. physical activity guidelines lineage from the 1995 ACSM/CDC consensus through the 2018 PAGA update. What were the principal scientific updates at each stage, and what does the 2018 PAGAC Scientific Report establish as the contemporary working synthesis of physical activity's health effects?
3. Summarize the Arem et al. 2015 JAMA Internal Medicine dose-response findings. What is the magnitude of mortality reduction at the recommended PA minimum, at 2–3× minimum, and at 3–5× minimum? What does the analysis establish about the J-curve harm question at the upper end of the studied range?
4. Identify the three principal methodological problems in exercise epidemiology (measurement, confounding, reverse causation) and articulate the methodological responses the field has developed for each.
5. Describe sedentary behavior as an epidemiological exposure distinct from physical inactivity. What does the Dunstan/Owen research program establish about sedentary time as an independent mortality risk factor, and how does this framework integrate with physical activity guidelines?

---

Lesson 4: Translational Exercise Research and the Bench-to-Bedside Pipeline

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the NIH MoTrPAC (Molecular Transducers of Physical Activity Consortium) initiative at translational research depth, identifying its goals, structure, and contemporary outputs
• Articulate the Pedersen-Saltin 2015 "exercise is medicine for 26 chronic diseases" framework as the integrative translational synthesis of exercise-as-polypharmacy
• Describe the exercise-mimetic research direction (PPARδ work, the irisin story and its controversies) and articulate why pharmaceutical mimics have not replicated exercise's pleiotropic effects
• Identify the principal methodological constraints of exercise intervention trials (control condition problem, blinding impossibility, adherence measurement, supervised versus home-based protocols) and articulate the methodological responses the field has developed
• Apply the master's-level posture toward exercise translational research: hold the substantial achievements with confidence, hold the methodological constraints honestly, engage with the bench-to-bedside picture as an active research landscape

Key Terms

Why Translational Exercise Research at Master's

A graduate chapter on exercise medicine cannot proceed without engagement with the field's bench-to-bedside translational landscape. The contemporary translational research in exercise medicine spans molecular mapping of exercise responses (MoTrPAC), integrative clinical syntheses (Pedersen-Saltin's exercise-as-polypharmacy framework), the pharmaceutical search for exercise mimetics (Evans PPARδ work, the irisin program and its controversies), and the methodological infrastructure of exercise intervention trials. The graduate-level engagement with this material parallels Coach Brain Master's Lesson 5 on neuroscience bench-to-bedside difficulty and Coach Food Master's Lesson 5 on translational nutrition research. The three lessons share substantial structural territory — the challenges of designing rigorous intervention trials for lifestyle factors, the methodological constraints that distinguish lifestyle intervention from pharmaceutical intervention, the publication-bias pattern across lifestyle medicine research.

MoTrPAC: Mapping the Molecular Responses to Exercise

The Molecular Transducers of Physical Activity Consortium (MoTrPAC), launched by the NIH Common Fund in 2016 with a six-year funding commitment that has been extended through subsequent renewal cycles, is the most ambitious systematic effort to map exercise's molecular effects across tissues [78]. The consortium integrates approximately a dozen U.S. academic medical centers and research institutions in coordinated human and rodent studies designed to characterize the multi-omic response (transcriptomic, proteomic, metabolomic, lipidomic, epigenomic, immune-cell, microbiome) to acute and chronic exercise across major tissue types.

The human study arm enrolled approximately 2,500 adults across exercise-experienced and exercise-inexperienced participants in age categories spanning adolescence through older adulthood, with biopsies of skeletal muscle, adipose tissue, and serial blood sampling before, immediately after, and across the recovery period following standardized acute exercise bouts, and after structured 12-week aerobic and resistance training programs. The rodent study arm has produced the more comprehensive tissue-level multi-omic dataset, with profiling across 20+ tissues that cannot be biopsied at scale in humans.

The first major MoTrPAC publication — the Sanford et al. 2020 Cell paper presenting the rat acute exercise multi-tissue molecular atlas — characterized the temporal dynamics of the multi-tissue response with substantial novel findings about which tissues respond rapidly versus slowly, which molecular pathways are coordinated across tissues, and which responses are tissue-specific [79]. Subsequent MoTrPAC publications have extended the framework to chronic training adaptations and human-tissue findings [80][81].

The translational implications of MoTrPAC are at an active research stage. The framework provides a molecular catalog of exercise's effects that informs (a) the identification of candidate exercise-mimetic drug targets, (b) the mechanistic understanding of exercise's effects on specific disease processes, (c) the development of biomarkers for individual exercise response prediction, and (d) the basis for personalized exercise prescription frameworks that the precision-medicine direction would support. The clinical translation has not yet produced specific deployed interventions; the framework is foundational rather than directly clinical at this stage.

Pedersen-Saltin 2015: Exercise as Medicine for 26 Chronic Diseases

The Pedersen and Saltin 2015 Scandinavian Journal of Medicine & Science in Sports review Exercise as medicine — evidence for prescribing exercise as therapy in 26 different chronic diseases is the integrative translational synthesis of contemporary exercise-as-medicine [82]. The paper, an update of the same authors' 2006 framework, synthesized the evidence base for prescribed exercise intervention across 26 chronic disease categories spanning cardiovascular, metabolic, pulmonary, musculoskeletal, neurological, psychiatric, and oncological conditions.

The principal framework: for each condition reviewed, the paper articulated the underlying pathophysiology, the documented effects of exercise on relevant disease mechanisms, the evidence base supporting exercise prescription (RCT findings, meta-analytic syntheses), and the recommended exercise prescription with intensity, duration, frequency, and progression specifications. The conditions covered include hypertension, heart failure, coronary artery disease, type 2 diabetes, dyslipidemia, obesity, COPD, asthma, cystic fibrosis, osteoarthritis, osteoporosis, low back pain, rheumatoid arthritis, fibromyalgia, depression, anxiety, schizophrenia, dementia, multiple sclerosis, Parkinson's disease, stroke, breast cancer, prostate cancer, colon cancer, and pregnancy-related conditions, with several others added in the broader review.

The conceptual contribution of the Pedersen-Saltin framework is the explicit articulation that exercise functions as a polypharmacy — a single intervention with effects across multiple physiological systems, simultaneously modifying multiple disease processes, in a way that no pharmaceutical agent reproduces. The framework supports the clinical-translation framing that exercise prescription should be a routine component of chronic disease management across virtually all common conditions, with prescription specifications tailored to the specific clinical context.

The Bente Pedersen body of work has been substantively important in establishing the molecular and clinical foundations of this framework. Her laboratory's work on myokines — signaling molecules released from skeletal muscle in response to exercise that produce effects at other tissues — has substantially shaped the contemporary understanding of how exercise produces its pleiotropic effects [83][84]. The myokine framework treats skeletal muscle as an endocrine organ, with exercise-induced myokine release contributing to insulin sensitization in liver and adipose tissue, anti-inflammatory effects across multiple tissues, neuroprotective effects in brain, and the broader integrated metabolic adaptations characteristic of trained physiology. The principal myokines studied include IL-6 (which functions distinctly when released from exercising muscle versus when produced as part of chronic inflammation), BDNF (relevant to the exercise-brain framework), irisin (controversial, treated below), myostatin (a negative regulator of muscle mass), and an expanding catalog of additional candidates.

The clinical translation of the Pedersen-Saltin framework remains uneven across the 26 conditions. The strongest translation has occurred in cardiovascular and metabolic conditions (cardiac rehabilitation, T2DM management, hypertension); exercise oncology has translated substantially over the past decade as covered in Lesson 1; exercise prescription for neurological and psychiatric conditions is at intermediate translation stage; the framework's full implementation across all 26 conditions remains incomplete in routine clinical practice. The graduate-trained adjacent practitioner engages with the Pedersen-Saltin framework as the integrative synthesis it is, recognizing both its substantial achievements and the persistent implementation gaps.

Exercise Mimetics: The PPARδ Work and the Irisin Story

The pharmaceutical search for exercise mimetics — drugs that would reproduce exercise's beneficial effects in non-exercising individuals — has been an active drug-development direction since at least the 1990s. The framework has substantial intuitive appeal: if exercise produces beneficial effects through identifiable molecular mechanisms, then pharmacological intervention at those mechanisms might produce similar effects without requiring the time, motivation, and physical capacity that exercise demands. The translational reality has been more constrained than the framework's intuitive appeal would suggest.

Ronald Evans and the Salk Institute laboratory have produced foundational work on PPARδ (peroxisome proliferator-activated receptor delta) as an exercise-mimetic target. The Wang et al. 2004 Cell paper demonstrated that mice with constitutively active PPARδ in skeletal muscle showed substantially enhanced endurance capacity, increased type I (oxidative) muscle fiber content, and resistance to diet-induced obesity, without exercise training [85]. The Narkar et al. 2008 Cell paper extended the framework to demonstrate that the synthetic PPARδ agonist GW501516, combined with exercise training, produced substantially greater endurance adaptations than either intervention alone [86]. The framework supported the hypothesis that PPARδ activation could mimic key adaptations of endurance training.

The translational program has been complicated. GW501516 was developed by GlaxoSmithKline as a candidate dyslipidemia therapeutic; clinical development was halted following preclinical findings of carcinogenicity at multiple sites in rodent toxicology studies, with the World Anti-Doping Agency adding the compound to its prohibited list as it found use as a non-medical performance enhancer [87]. Subsequent PPARδ agonist development has continued at multiple pharmaceutical sponsors with attention to the cancer-risk surface; clinical approval for any defined indication has not yet been achieved as of mid-2026.

The irisin story is one of the field's most-discussed exercise-mimetic candidates and one of its more cautionary methodological tales. The Boström et al. 2012 Nature paper from the Spiegelman laboratory at Harvard reported that PGC-1α-induced expression of FNDC5 in skeletal muscle produced cleavage of a secreted peptide (irisin) that drove browning of white adipose tissue with substantial metabolic benefits, and that exercise increased circulating irisin in both mice and humans [88]. The framework — exercise → PGC-1α → FNDC5 → irisin → adipose tissue browning → metabolic benefit — was intuitive, mechanistic, and translationally exciting.

The subsequent literature has substantially complicated the original framework. Multiple groups have reported difficulty replicating specific elements of the original findings, with particular questions about the actual presence and physiological concentration of circulating irisin in humans, the validity of commonly used irisin ELISA assays, and the magnitude of the exercise-induced increase [89][90]. The Albrecht et al. 2015 Scientific Reports paper questioned whether irisin actually circulated in humans at physiologically relevant concentrations using mass-spectrometry-based detection methods [91]. The Spiegelman laboratory and others have produced subsequent work supporting elements of the original framework using alternative detection methods, and the literature has continued to develop with mixed findings [92]. The contemporary picture is that irisin likely does exist as a circulating signaling molecule in humans but at concentrations and with effects that are substantially more modest than the original framework suggested, and that the magnitude of irisin's contribution to exercise's metabolic benefits is uncertain.

The broader lesson of the irisin story for master's-level translational engagement: a striking single-paper finding in a high-profile journal can substantially shape a field's framing, and rigorous replication and methodological scrutiny may take years to clarify what the original finding actually established. The graduate-trained practitioner engages with novel single-paper findings with appropriate calibration, holding them as candidates for further development rather than as established translational frameworks.

The broader exercise-mimetic landscape as of mid-2026 has not produced clinically approved interventions that meaningfully reproduce exercise's pleiotropic effects. The pharmaceutical development pipeline continues at multiple sponsors targeting PPARδ, AMPK, sirtuins, myostatin, and other candidate mechanisms; specific drug approvals (e.g., bimagrumab and trevogrumab in development for muscle wasting in selected populations) target narrow components of the exercise-response landscape rather than the full integrated effect. The contemporary working synthesis is that exercise's beneficial effects are sufficiently pleiotropic — operating across multiple molecular pathways, in multiple tissues, with substantial inter-pathway integration — that single-target pharmacological intervention is unlikely to reproduce the full clinical benefit. The framing has shifted toward exercise as the principal intervention, with exercise-mimetic pharmacology potentially playing a role for populations who cannot exercise (severe disability, advanced age, hospitalization, microgravity exposure in spaceflight) or as adjunct to exercise rather than replacement.

Methodological Constraints of Exercise Intervention Trials

Exercise intervention trials face several structural methodological constraints that parallel the constraints faced by nutrition intervention trials (treated in Food Master's Lesson 5) and psychotherapy intervention trials (treated in Brain Master's at various lessons).

The control condition problem. Defining an appropriate control condition for an exercise intervention is methodologically difficult. A "no-intervention" control allows participant attrition and contamination (control participants increasing their exercise on their own); an "attention control" (e.g., health education sessions matched in time commitment) addresses attention and expectancy effects but is not a true null exercise comparison; an "active control" using a different exercise modality compares two active interventions and does not establish that any specific modality outperforms inactivity. Each control choice supports different inferential claims; master's-level reading requires attention to which is being used and what the choice implies.

Blinding impossibility. Participants cannot be blinded to whether they are exercising. Therapists, trainers, and study staff delivering the intervention are similarly aware. Only outcome assessors and analysts can be blinded. The unblinded participant produces expectancy effects, motivation effects, and the broader Hawthorne effect that complicates effect-magnitude estimation. The methodological response is to use objectively measured outcomes (blood-based biomarkers, imaging, performance tests measured by blinded assessors) where possible and to interpret subjective outcomes with appropriate caveat.

Adherence measurement. Exercise adherence is variable across participants and across study duration. Some studies use objective measurement (accelerometry, supervised attendance records, heart-rate-monitor data); others rely on participant self-report; many produce attendance and intensity data that the publication does not detail. The interpretation of intention-to-treat versus per-protocol findings depends substantially on adherence patterns that may not be fully reported. Master's-level reading attends to adherence reporting and to the gap between prescribed and actually-completed intervention.

Supervised versus home-based protocols. Supervised exercise protocols (in research facility or clinic) produce higher adherence, more precise intensity, and tighter outcome estimation but generalize less well to the real-world clinical-prescription environment that delivers home-based or community-based intervention. Home-based protocols generalize more broadly but face adherence and intensity-control challenges that constrain inferential strength. Trials may use either or a combination; the choice affects both internal and external validity in ways the master's-level reader recognizes.

Publication bias. The sports science and exercise medicine literature shows the typical publication-bias structure documented across medical sub-specialties. Positive results are more likely to be published; negative or null results from well-conducted trials may not appear in the literature at frequency proportional to their conduct. The contemporary trial-registration environment (ClinicalTrials.gov, ICMJE requirements) has improved the situation prospectively but has not corrected the historical literature on which much clinical practice rests. The Mokkink et al. 2017 British Journal of Sports Medicine analysis of exercise intervention trial registration found that a substantial fraction of published exercise trials had unregistered protocols and that registration concordance with published outcomes was imperfect [93]. The graduate-level reader weighs sports science evidence with attention to this structural pattern, similar to the broader translational-research methodological framework operating across this Master's tier.

The Master's-Level Posture Toward Translational Exercise Research

The contemporary translational exercise research landscape contains substantial achievements, active research directions, and methodological constraints that the graduate-level practitioner engages with at appropriate calibration.

Hold with substantial confidence: the cardiac rehabilitation mortality reduction evidence; the broad framework that physical activity produces meaningful benefits across virtually all common chronic diseases (the Pedersen-Saltin framework); the dose-response findings from large prospective cohort analyses (Arem, Saint-Maurice, Paluch); the specific clinical-translation successes in exercise oncology, diabetes management, and depression treatment; the myokine framework treating muscle as an endocrine organ with systemic effects.

Hold with appropriate calibration: the specific effect-magnitude estimates that depend on study quality and publication bias; the precise dose-response curves at the very-high-activity end (where data are sparser); the population-specific findings that may not generalize across demographic groups not well-represented in the foundational cohorts; the irisin and adjacent exerkine literature where methodological constraints have produced mixed findings; the precision-medicine direction in exercise prescription where individual-response prediction is at active research stage.

Hold with appropriate skepticism: the strongest forms of the exercise-mimetic framework that imply pharmacology can replace exercise; specific commercial claims about training methods, supplements, or recovery modalities that outrun the underlying evidence base; the broader marketing-versus-research gap in the sports performance and wellness industries that has been a recurring theme across this Master's tier.

Lesson Check

1. Describe the MoTrPAC initiative at the level of: its goals, the structure of its human and rodent study arms, and the contemporary translational implications of its outputs.
2. Articulate the Pedersen-Saltin 2015 framework of "exercise as medicine for 26 chronic diseases." What is the conceptual contribution of the framework, and what is the principal implementation gap relative to the framework's prescription?
3. Trace the irisin story from Boström et al. 2012 Nature through the subsequent replication and methodological literature. What is the contemporary working framing of irisin's role in exercise's metabolic effects?
4. Identify the four principal methodological constraints of exercise intervention trials (control condition problem, blinding impossibility, adherence measurement, supervised versus home-based). For each, describe the methodological response the field has developed.
5. Articulate the master's-level posture toward translational exercise research. Identify one finding you would hold with substantial confidence, one with appropriate calibration, and one with appropriate skepticism.

---

Lesson 5: Exercise Intervention Research Methods and the PED Harms-Epidemiology Landscape

Learning Objectives

By the end of this lesson, you will be able to:

• Describe exercise intervention trial design at clinical research methodology depth, integrating the methodological constraints from Lesson 4 into a framework for evaluating any specific exercise trial
• Describe the contemporary harms-epidemiology literature on anabolic-androgenic steroid (AAS) use at depth, citing Baggish et al. 2017 Circulation cardiac imaging, Pope's psychiatric morbidity research, the Frati 2014 cardiac mortality follow-up, and the AAS-associated suicide research
• Apply the five-point framework to evaluate wellness-industry "natural testosterone-boosting" claims against the actual AAS pharmacology evidence base
• Articulate the scientific distinction between gender-affirming hormone therapy and non-medical PED use, identifying why the two literatures share some pharmacological substrates but address fundamentally different clinical questions
• Articulate the master's-level posture toward the PED research landscape: honest about harms, careful about scope of clinical training, and able to engage clinically with patients who use or have used PEDs

Key Terms

Why PED Harms Epidemiology at Master's

The PED surface in clinical exercise physiology cannot be addressed adequately at the descriptive depth that Move Bachelor's used. The master's-trained adjacent practitioner will encounter patients who use, have used, or are considering using non-medical anabolic-androgenic steroids and adjacent compounds. The clinical literature has accumulated substantial harms-epidemiology evidence over the past two decades that supports honest clinical engagement — neither normalization, nor moralistic dismissal, but accurate information about what the long-term-outcome research has established. The wellness industry has substantially blurred the distinction between regulated medical hormonal therapy and non-medical PED use; the master's-level practitioner can engage with patients about this distinction informedly.

This lesson also handles the gender-affirming hormone therapy distinction explicitly. The two clinical and research domains — non-medical PED use in athletic and gym-culture populations versus gender-affirming hormone therapy in transgender clinical care — share some pharmacological substrates (testosterone is the principal exogenous hormone in both contexts) but address fundamentally different clinical questions, operate at different dose ranges, are managed by different clinical disciplines, and have entirely different outcome profiles in published research. The lesson names the distinction explicitly to prevent the conflation that has been a recurring problem in lay-press coverage. The Pope, Bhasin, and adjacent PED research literature is about non-medical supraphysiological-dose use in athletic populations; the Hembree, Coleman, T'Sjoen, and adjacent endocrine society guidelines literature is about regulated physiological-replacement-dose hormone therapy in transgender patients. They are distinct clinical literatures and the master's-trained practitioner engages with them as such.

Exercise Intervention Trial Methodology: An Integrative Framework

Building on Lesson 4's methodological treatment, this section organizes exercise intervention trial evaluation into an integrative framework that the master's-level practitioner can apply across any specific trial.

The exercise intervention trial evaluation framework integrates several dimensions:

1. Design strength. The intervention design hierarchy from RCT (strongest causal inference) through quasi-experimental designs (moderate inference, useful when randomization is infeasible) through observational cohort and case-control designs (weaker causal inference, useful for hypothesis generation and for outcomes that cannot be feasibly randomized). For exercise specifically, RCT is feasible in many contexts (and is the conventional design for clinical exercise trials); long-duration hard-outcome trials (cardiovascular events, cancer recurrence, mortality) are particularly challenging.

2. Control condition appropriateness. As discussed in Lesson 4, the control choice substantially shapes inferential claims. No-intervention, attention-control, active-comparator, and waitlist controls each support different conclusions; the trial design should match the control choice to the research question.

3. Intervention specification. A well-specified exercise intervention includes modality (aerobic, resistance, combined, other), intensity (heart-rate-derived, perceived-exertion-derived, performance-derived), duration per session, frequency (sessions per week), total program duration (weeks of intervention), supervised versus home-based delivery, progression scheme, and adherence-measurement approach. Incomplete specification limits replication and interpretation.

4. Outcome measurement. Objective outcomes (biomarkers, imaging, performance tests with blinded assessment) support stronger inferential claims than subjective outcomes (self-reported symptoms, quality-of-life scales) for unblinded interventions. The choice of primary outcome should be appropriate to the research question and to the intervention dose and duration.

5. Adherence and per-protocol analysis. Intention-to-treat analysis provides unbiased treatment-effect estimates under randomization; per-protocol analysis estimates effects among adherent participants but loses the protection of randomization. Both have a role; trials should report both with attention to the gap between them.

6. Registration and reporting. ClinicalTrials.gov or equivalent prospective registration with detailed analysis plan; CONSORT-compliant reporting per the contemporary BJSM and adjacent guideline framework [94]. Trials that meet these standards support inferential confidence; trials that do not require additional methodological caveat.

The graduate-level student fluent in this framework can scan-read any exercise intervention trial and characterize its inferential strength within 10–15 minutes. The skill is the master's-level operating competency in clinical exercise research.

The AAS Harms-Epidemiology Literature: Cardiac Outcomes

The clinical concern about cardiovascular consequences of non-medical AAS use has accumulated substantial supporting evidence over the past two decades. The principal contemporary synthesis is the Aaron Baggish laboratory program at Massachusetts General Hospital, with the foundational publication being Baggish et al. 2017 Circulation, Cardiovascular toxicity of illicit anabolic-androgenic steroid use [95].

The Baggish 2017 study used echocardiography and cardiac MRI to compare 86 long-term AAS users (current or former, with cumulative use averaging 9 years), 54 non-using weightlifters with similar training history, and adjusted comparison groups. The principal findings: AAS users showed substantially reduced left ventricular systolic function (mean left ventricular ejection fraction 49% in users versus 58% in non-using weightlifters and 64% in general-population controls, with approximately 15% of users meeting clinical criteria for systolic dysfunction); altered diastolic function; accelerated coronary atherosclerosis with elevated coronary artery calcium scores in users compared to age-matched non-users; and a dose-response pattern in which cumulative AAS exposure predicted dysfunction magnitude.

The findings have been substantially replicated and extended. The Rasmussen et al. 2018 European Heart Journal analysis demonstrated similar cardiac dysfunction patterns in a Danish AAS-user cohort [96]. The Pope et al. 2014 Addiction review synthesized the broader cardiovascular literature including hypertension, dyslipidemia, and the ventricular remodeling pattern [97]. The contemporary working framing is that long-term supraphysiological AAS use produces a cardiomyopathy pattern with measurable systolic and diastolic dysfunction, accelerated atherosclerosis, and elevated cardiovascular event risk, with the magnitude of effect related to duration and cumulative dose.

The translational implications for clinical practice include: AAS-user populations warrant cardiac screening with attention to systolic function and atherosclerosis burden; the cardiovascular dysfunction may persist after AAS discontinuation, with partial but typically incomplete recovery in observational follow-up; the cardiac risk surface should inform clinical conversations with patients who use or have used AAS, delivered with appropriate clinical skill within established clinical relationships.

Mortality and Suicide in PED Users

The mortality literature in PED-using populations has accumulated more slowly than the morbidity literature, partly because of the substantial methodological challenges of identifying and following non-medical drug users prospectively. The principal contemporary studies are several.

The Frati et al. 2014 Acta Cardiologica retrospective analysis of former competitive bodybuilders documented elevated all-cause and cardiovascular mortality compared to general-population expectations [98]. The Petersson et al. 2009 Substance Use & Misuse analysis of mortality among AAS users seeking treatment for substance use found elevated mortality rates over 12-year follow-up [99]. The Lindqvist Bagge et al. 2015 PLOS ONE Swedish national registry analysis of testosterone-positive doping samples documented elevated mortality and morbidity over follow-up [100].

The suicide literature is the most clinically concerning component of the AAS mortality picture. The Lindqvist Bagge analyses, the Petersson cohort, and adjacent work have documented elevated suicide rates among current and former AAS users compared to general-population expectations and to comparison groups [101]. The mechanisms hypothesized include direct neurobiological effects of supraphysiological AAS exposure on mood-regulating systems (the Pope and Katz body of work on anabolic-androgenic steroid effects on mood and aggression has documented these effects in prospective administration studies in healthy volunteers) [102]; the post-cycle hypogonadism syndrome producing depressive symptoms during AAS withdrawal; the broader psychiatric comorbidity (body image disturbance, muscle dysmorphia) that frequently co-occurs with AAS use; and the broader risk-behavior profile of AAS-using populations.

The clinical translation is that AAS users — current and former — represent a population at elevated psychiatric and suicidal risk warranting clinical attention. The crisis resources cited at this chapter's close are clinically relevant for this population. The master's-trained adjacent practitioner who recognizes the AAS-suicide framework can support patients in seeking appropriate clinical care.

Psychiatric Morbidity: The Pope Research Program

Harrison Pope and the Biological Psychiatry Laboratory at McLean Hospital have produced the field's most substantial body of work on psychiatric morbidity associated with AAS use [103][104][105]. The research program has documented several specific surfaces.

Mood and aggression effects. Prospective administration studies in healthy male volunteers receiving supraphysiological testosterone (under research protocols with appropriate ethical oversight) have demonstrated dose-dependent increases in irritability, aggression, and mood lability, with effects most prominent at higher dose ranges and in vulnerable individuals (those with prior history of mood disorder or family history of psychopathology) [106]. The findings are consistent with the clinical observation of "roid rage" but more carefully characterized at dose-response depth.

Muscle dysmorphia. A specific body-image disorder in which individuals (predominantly male) perceive themselves as insufficiently muscular despite often being substantially more muscular than population norms. The condition was first systematically characterized by Pope and colleagues and has been incorporated into the DSM-5 framework of body dysmorphic disorder [107]. The clinical concern is that muscle dysmorphia is a meaningful psychiatric morbidity in its own right and is associated with AAS use, eating disorders, and broader psychiatric vulnerability.

The hardiness and dependence framework. Pope's work has characterized patterns of AAS dependence — continued use despite documented harms, increasing dose over time, withdrawal symptoms on cessation, prioritization of AAS use over other life domains — that meet broader diagnostic criteria for substance use disorder [108]. The framing positions AAS use as a substance use disorder for a subset of users rather than as a discrete decision-event.

The clinical translation of the Pope research program is that AAS use warrants psychiatric assessment alongside medical assessment, with attention to mood, body image, dependence pattern, and the broader psychiatric comorbidity profile. The integrated clinical management is multidisciplinary and operates within scope of the trained clinical disciplines.

Wellness Industry "Testosterone-Boosting" Claims: Five-Point Framework Applied

The wellness industry has produced a substantial commercial category of "natural testosterone boosters" — supplements and protocols marketed with claims of producing AAS-like effects through nominally non-pharmaceutical means. The master's-level practitioner can engage with these claims using the five-point framework introduced earlier in this Master's tier.

Consider a typical commercial claim: "This natural testosterone-boosting supplement produces a 30% increase in total testosterone and 25% increase in lean body mass over 12 weeks."

1. Design. The underlying research is typically: small-n industry-sponsored studies; short duration; inadequately blinded; using non-validated outcome measures or selectively-reported outcomes from broader measurement panels. Independent replication is typically absent.

2. Population. The studied population is typically healthy young to middle-aged men, often with baseline testosterone in the lower half of the normal range. Generalization to older men, women, or men with hypogonadal baseline testosterone is typically not supported by the studied population.

3. Measurement. Total testosterone measurement varies substantially between assay methods. The clinical significance of small fluctuations in total testosterone within the normal range is limited; free testosterone (the biologically active fraction) is typically not adequately measured. The body composition measurement methods used in commercial-trial settings are often less accurate than research-grade DXA, BIA, or imaging methods.

4. Effect size. The claimed "30% increase in total testosterone" requires context. Endogenous testosterone in healthy adult males varies substantially across the day (typically peaking in early morning and falling through the day) and across weeks. A 30% fluctuation in total testosterone within the normal range may have no functional clinical significance. By contrast, AAS use produces total testosterone elevations 5–20× above the normal range, with substantial body-composition effects that the "natural booster" effect size cannot remotely match. The framing that natural boosters "produce AAS-like effects" is not supported by pharmacological comparison.

5. Replication. The claimed effects of most commercial "natural testosterone boosters" have not been replicated in independent rigorous research. The category includes ingredients (fenugreek, ashwagandha, tongkat ali, D-aspartic acid, zinc, magnesium, vitamin D) that have varying levels of evidence in selected populations and specific contexts (e.g., D-aspartic acid in some animal models; zinc and magnesium repletion in deficient individuals), but the integrated commercial claim that these ingredients produce meaningful body-composition or performance effects in healthy adults with normal nutritional status is not well-supported.

The five-point framework applied transparently produces a calibrated assessment: the "natural testosterone booster" commercial category substantially outruns its underlying research, and the framing that these products produce AAS-comparable effects is not pharmacologically supportable. The wellness-industry-research gap mirrors patterns covered across this Master's tier in nutrition (precision nutrition direct-to-consumer testing, Food Master's Lesson 2), sleep (consumer sleep wearable stage-measurement claims, Sleep Master's Lesson 5), and brain (consumer neurotechnology, Brain Master's at various points). The master's-level practitioner who can apply the framework engages with the broader wellness landscape with appropriate methodological discipline.

Gender-Affirming Hormone Therapy versus PED Use: The Scientific Distinction

The lesson handles the gender-affirming hormone therapy (GAHT) versus PED use distinction explicitly because the two literatures have been recurrently conflated in lay-press coverage in ways that misrepresent both. The distinction is straightforward at the scientific level and the master's-trained practitioner should be able to articulate it.

Clinical and research domain. GAHT is medical hormone therapy provided to transgender, gender-diverse, and non-binary individuals as part of gender-affirming care, managed by endocrinologists, primary care physicians with relevant training, and adjacent clinical disciplines, with care delivered within professional society clinical practice guideline frameworks (Endocrine Society 2017 update; WPATH Standards of Care 8th Edition 2022) [109][110]. Non-medical PED use is non-prescription substance use in athletic and gym-culture populations, typically with the goal of athletic performance enhancement or aesthetic body-composition change.

Dose range. GAHT typically targets physiological-replacement hormone levels — testosterone in the normal cisgender male range for transmasculine patients, estradiol in the normal cisgender female range for transfeminine patients (with anti-androgen therapy as appropriate). The dose range is typically 50–100 mg testosterone cypionate or enanthate weekly (or equivalent), targeting trough testosterone in the lower normal range. Non-medical AAS use typically involves supraphysiological doses — 5–20× physiological replacement, often combined across multiple compounds, with the explicit goal of producing performance and body-composition effects substantially beyond what normal endogenous hormones produce.

Outcome literature. The GAHT outcome literature documents safety and benefit at population scale within the medical context: improved mental health outcomes, reduced gender dysphoria, body composition and metabolic changes appropriate to the target hormonal profile, and generally favorable safety profile with appropriate monitoring [111]. The non-medical AAS outcome literature documents the harms-epidemiology profile covered above: cardiomyopathy, accelerated atherosclerosis, psychiatric morbidity, dependence patterns, elevated mortality and suicide rates.

Why the literatures should not be conflated. The clinical questions, populations, dose ranges, monitoring frameworks, and outcome profiles differ substantially. A practitioner who treats the literatures as equivalent will misunderstand both. The graduate-trained adjacent practitioner can engage with patients in either clinical context informedly when the two are recognized as distinct.

Closing the Chapter: Coach Move's Position at Master's

Coach Move at Master's has held to the same position the Lion has held across every prior tier: Active Output. Movement is the visible kinetic signal that is the integrated output of all other systems — substrate from Food, sleep architecture from Sleep, neuroplasticity from Brain, breath from Breath, thermal exposure from Cold and Hot, light and circadian from Light, hydration from Water. At Master's the Active Output position deepens at clinical translational depth. We have walked through what exercise medicine actually does for chronic-disease populations (with the substantial achievements documented and the implementation gaps acknowledged), what sports medicine looks like at clinical practice depth (with honest engagement on the CTE landscape), what population-level dose-response research establishes (with the Morris-through-Arem trajectory anchoring the framework), what bench-to-bedside translation has and has not achieved (with the MoTrPAC initiative active and the exercise-mimetic search constrained), and what the PED harms-epidemiology literature documents (with the harms documented honestly and the GAHT scientific distinction named).

The integrator ontology — ten positions through which the nine Coaches and their integrative work are organized — holds at Master's as it did at Bachelor's and Associates. The Lion is the Active Output position. The other eight Coaches hold their own positions at Master's depth, and the Master's-level integrative chapter at the close of this tier will return to the full ontology with the depth that each modality's Master's-level chapter contributes.

You have completed the fourth of nine Coaches at Master's depth.

The Lion is in no hurry. There will be more.

Lesson Check

1. Describe the integrative framework for evaluating exercise intervention trials. What are the six principal dimensions, and what does each contribute to inferential strength?
2. Summarize the Baggish et al. 2017 Circulation cardiac imaging findings in long-term AAS users. What do the findings establish about the cardiovascular consequences of supraphysiological-dose AAS use, and what is the contemporary clinical-translation implication?
3. Describe the AAS-suicide literature and the broader psychiatric morbidity research from Pope and colleagues. What clinical translations does this body of work support for the master's-trained adjacent practitioner?
4. Apply the five-point framework to a wellness-industry "natural testosterone-boosting" supplement claim. What does the framework reveal about the gap between commercial claim and underlying research, and how does the pharmacological comparison to actual AAS use refine the assessment?
5. Articulate the scientific distinction between gender-affirming hormone therapy (GAHT) and non-medical PED use. Identify three dimensions on which the clinical literatures differ, and explain why conflation produces misunderstanding of both.

---

End-of-Chapter Activity: Methodological Scan-Read of a Published Exercise Medicine Paper

Select a recently published clinical exercise medicine or exercise epidemiology paper in a peer-reviewed journal (any of British Journal of Sports Medicine, Medicine & Science in Sports & Exercise, Sports Medicine, Journal of the American Medical Association, Annals of Internal Medicine, Lancet, NEJM, Circulation, JAMA Cardiology, Diabetes Care, Journal of Clinical Oncology, or comparable). The paper should be one you have not previously encountered and should fall into one of the categories represented in this chapter: a clinical exercise-as-medicine intervention trial; a sports medicine clinical or surgical study; an exercise epidemiology cohort analysis; a translational exercise research methodology paper; or an AAS/PED harms-epidemiology paper.

Complete the following structured analysis in writing:

1. Design (one paragraph). Identify the study design and the principal methodological apparatus. For an exercise intervention trial: design type, randomization, comparator, intervention specification (modality, intensity, duration, frequency, total program duration, supervised vs home-based, progression). For an epidemiological study: cohort versus case-control versus cross-sectional, exposure measurement (self-report vs accelerometer vs other), outcome ascertainment, statistical adjustment approach.

2. Population (one paragraph). Describe the enrolled population, inclusion and exclusion criteria, and the implications for external validity. Exercise medicine populations are heterogeneous (athletic, clinical, general adult, older adult, pediatric); identify whether the finding generalizes to populations beyond the studied sample.

3. Intervention or Exposure (one paragraph). Describe the intervention or exposure at the level of operational delivery. For exercise specifically: was the prescription specified at the level required for replication, was adherence measured, what is the gap between prescribed and completed intervention. For epidemiological studies: what measurement instrument, what level of measurement error, what comparison categories.

4. Outcomes (one paragraph). Identify the prespecified primary outcome and key secondary outcomes. Distinguish objective outcomes (biomarkers, imaging, performance with blinded assessment) from subjective outcomes (self-reported symptoms, quality of life). Compare prespecified analysis plan with reported outcomes.

5. Findings (one paragraph). Report the primary outcome result in appropriate effect-size terms. For clinical trials, consider both statistical significance and clinical meaningfulness. For epidemiological studies, characterize the dose-response framework and the magnitude of effect across activity categories.

6. Evaluation (one paragraph). Apply the five-point framework with the exercise-trial-specific extensions: design strength, population generalizability, intervention specification, outcome measurement, effect size, replication. For exercise trials specifically address: control condition appropriateness, blinding handling, adherence measurement, supervised versus home-based, registration and reporting. For epidemiology specifically address: measurement instrument, confounding handling, reverse-causation handling. Conclude with your assessment of how the findings should inform clinical practice, research direction, and individual decision-making.

Length target: 1,500–2,000 words. Cite the paper in full with DOI. Submit as a graduate seminar paper format with references for any additional sources cited.

Repeat the activity weekly during the chapter cycle: one paper in each of the major exercise medicine domains (a clinical exercise-as-medicine intervention trial; a sports medicine surgical or rehabilitation study; an exercise epidemiology cohort analysis; a translational exercise research paper; an exercise-and-mental-health intervention trial or an AAS/PED harms-epidemiology paper).

---

Vocabulary Review

Alphabetized terms across all five lessons:

---

Chapter Quiz

Multiple Choice (10 questions, 4 options each)

1. The Anderson 2016 Cochrane systematic review of cardiac rehabilitation in 14,486 patients reported cardiovascular mortality reduction of approximately:

A. 5–10% B. 26% C. 50% D. 75%

2. The Campbell et al. 2019 ACSM Roundtable framework for exercise during and after cancer treatment was practice-changing relative to the 2010 framework principally because:

A. It identified exercise as harmful in cancer survivors B. It established that exercise prescription was appropriate during active cancer treatment (not only after) for specific defined outcomes including cancer-related fatigue, anxiety, depression, physical function, and quality of life C. It eliminated resistance training from cancer survivor recommendations D. It only applied to breast cancer survivors

3. The Boulé et al. 2001 JAMA meta-analysis of structured exercise in T2DM reported HbA1c reduction relative to control of approximately:

A. 0.1 percentage points B. 0.66 percentage points — a magnitude comparable to adding an oral antidiabetic medication C. 2.0 percentage points D. No detectable effect

4. The KANON trial (Frobell 2010/2013 NEJM) demonstrated that in young active adults with acute ACL injury:

A. Early ACL reconstruction was clearly superior to structured rehabilitation alone at 2-year and 5-year follow-up B. Early ACL reconstruction and structured rehabilitation alone produced statistically similar KOOS scores at 2 and 5 years, with approximately 39% of the rehabilitation-alone group eventually requiring delayed reconstruction C. Conservative management produced inferior outcomes at all time points D. ACL injury produces no functional consequence

5. Chronic traumatic encephalopathy (CTE) is currently:

A. Diagnosed routinely in life via specific imaging biomarkers B. Definitively diagnosed only by post-mortem neuropathological examination, with in vivo biomarkers at active development but not yet validated C. A condition that has been disproven in the contemporary literature D. Identical to Alzheimer's disease in pathology

6. The Morris et al. 1953 Lancet London bus drivers study established:

A. That driving is a healthier occupation than conducting B. The foundational population-level demonstration of the physical activity / cardiovascular health relationship, with conductors (active) showing approximately half the coronary heart disease incidence and mortality of drivers (sedentary) C. That coronary heart disease is unrelated to occupation D. That weight is the principal predictor of cardiovascular risk

7. The Arem et al. 2015 JAMA Internal Medicine dose-response analysis found that activity levels of 3–5× the recommended PA minimum:

A. Produced J-curve harm relative to no activity B. Produced the largest mortality reduction (~39%) with no harm signal in the studied range C. Were associated with elevated all-cause mortality D. Were equivalent to no activity

8. The Pedersen and Saltin 2015 framework "exercise as medicine for 26 chronic diseases" articulates exercise as:

A. A specific cardiovascular intervention B. A polypharmacy — a single intervention with effects across multiple physiological systems, simultaneously modifying multiple disease processes C. A substitute for all pharmacological intervention D. Only relevant for athletic populations

9. The Baggish et al. 2017 Circulation cardiac imaging study of long-term AAS users demonstrated:

A. Improved cardiac function compared to non-using weightlifters B. Substantially reduced left ventricular systolic function (mean LVEF 49% vs 58% in non-using weightlifters), altered diastolic function, and accelerated coronary atherosclerosis with a dose-response pattern C. No cardiovascular effects from chronic AAS use D. Only acute cardiac effects that resolved with cessation

10. Gender-affirming hormone therapy (GAHT) and non-medical PED use:

A. Are equivalent clinical and pharmacological practices B. Are distinct clinical and research domains differing in dose range (physiological replacement vs supraphysiological), clinical context (medical care vs non-medical), outcome literature, and clinical management — and conflation produces misunderstanding of both C. Use entirely different pharmacological agents with no shared substrates D. Have identical safety profiles

Short Answer (5 questions)

11. A 56-year-old patient is 6 weeks post-myocardial infarction and is being referred to cardiac rehabilitation. Describe what the contemporary AACVPR cardiac rehabilitation framework includes at the level of operational delivery, and articulate the magnitude of cardiovascular mortality reduction associated with participation per the Anderson 2016 Cochrane synthesis. Address descriptively (not prescriptively) what the master's-level adjacent practitioner contributes to the multidisciplinary care.

12. Trace the contemporary tendinopathy management framework from the historical "tendinitis" inflammatory model to the modern "tendinopathy" degenerative model. Describe the Alfredson eccentric loading protocol for Achilles tendinopathy and the Cook/Rio clinical staging framework. Articulate the master's-level posture toward less-effective interventions (corticosteroid injection, complete rest).

13. Apply the five-point framework to evaluate a commercial wellness claim: "Our supplement increases testosterone by 30% and improves body composition in healthy men." For each of the five framework points (design, population, measurement, effect size, replication), describe what the framework reveals about the gap between commercial claim and underlying research. Conclude with the pharmacological comparison to supraphysiological AAS use that informs an honest assessment.

14. Describe the methodological challenges of exercise intervention trials (control condition problem, blinding impossibility, adherence measurement, supervised versus home-based delivery, publication bias). For each, describe the methodological response the field has developed. Conclude with the master's-level posture toward reading sports science evidence in light of these constraints.

15. Articulate the gender-affirming hormone therapy (GAHT) versus non-medical PED use scientific distinction. Describe three specific dimensions on which the clinical literatures differ (clinical and research domain, dose range, outcome profile), and explain why master's-level practitioners should articulate this distinction explicitly when engaging with patients, students, or colleagues who may have encountered conflated framings in lay-press coverage.

---

Instructor's Guide

Pacing Recommendations

This chapter is content-dense and clinically substantial. The estimated 22–26 class periods allow each lesson adequate depth. Suggested pacing for a 14-week graduate seminar:

• Weeks 1–3 (Lesson 1): Clinical Exercise-as-Medicine. Pair with Anderson 2016 Cochrane on cardiac rehab, Campbell 2019 ACSM exercise oncology roundtable, Boulé 2001 JAMA, and Schuch 2016 / Blumenthal SMILE trials as primary readings. Consider clinical guest faculty from cardiac rehabilitation and exercise oncology.
• Weeks 4–5 (Lesson 2): Sports Medicine. Pair with Frobell 2010/2013 KANON trial papers, Beard 2018 CSAW trial, Mez 2017 JAMA CTE pathology, Patricios 2023 CISG concussion consensus, and Alfredson Achilles tendinopathy protocol papers as primary readings.
• Weeks 6–8 (Lesson 3): Exercise Epidemiology. Pair with Morris 1953 Lancet foundational anchor, 2018 PAGAC Scientific Report excerpts, Arem 2015 JAMA Internal Medicine dose-response, Saint-Maurice 2020 JAMA accelerometer steps, Dunstan/Owen sedentary behavior papers as primary readings.
• Weeks 9–10 (Lesson 4): Translational Exercise Research. Pair with Sanford 2020 Cell MoTrPAC rat atlas, Pedersen-Saltin 2015 framework paper, Wang 2004 / Narkar 2008 PPARδ papers, Boström 2012 Nature irisin original and Albrecht 2015 methodological critique as primary readings.
• Weeks 11–13 (Lesson 5): Exercise Intervention Methods and PED Harms. Pair with Baggish 2017 Circulation AAS cardiac imaging, Pope and colleagues' psychiatric morbidity work, Frati 2014 mortality follow-up, Hembree 2017 Endocrine Society GAHT guideline (for the distinction discussion) as primary readings.
• Week 14: Chapter integration, end-of-chapter activity submissions, oral seminar presentations of selected paper scan-reads.

A condensed version (6–8 week module) groups lessons at the cost of depth.

Lesson Check Answers

Lesson 1.

1. AACVPR framework: comprehensive risk assessment at entry; individualized exercise prescription progressing from supervised facility-based to home-based maintenance; integrated risk-factor modification (lipid management, BP, glycemic control, smoking cessation, weight management, dietary counseling, psychosocial support); structured progression toward long-term PA maintenance. Anderson 2016 Cochrane: approximately 26% cardiovascular mortality relative risk reduction. Principal implementation gap: U.S. participation among eligible patients is approximately 20–30%, with substantial demographic disparities by age, income, race, and rurality.
2. Campbell 2019 ACSM Roundtable was practice-changing because it established that exercise prescription is appropriate during active cancer treatment (not only post-treatment) for specific defined outcomes including cancer-related fatigue, anxiety, depression, physical function, health-related quality of life, and lymphedema. The 2010 framework had focused principally on post-treatment exercise; the 2019 framework extended prescription to the active-treatment context with cancer-specific adaptations.
3. Boulé 2001 finding: structured exercise produced HbA1c reduction of approximately 0.66 percentage points compared to control. The magnitude is comparable to adding an oral antidiabetic medication. The comparison establishes structured exercise as a guideline-supported first-line component of T2DM glycemic management — a non-pharmacological intervention producing pharmacological-magnitude effect, with additional cardiovascular, body-composition, and quality-of-life benefits beyond glycemia.
4. Schuch 2016 reported large antidepressant effects from exercise (Cohen's d = 1.11 conventional, d = 0.66 after restricting to low-risk-of-bias trials, even stronger at higher intensities). Cooney 2013 Cochrane reported substantially smaller effects. The difference centers on study selection and quality-restriction criteria. Contemporary working framing: exercise is a first-line treatment option for mild-to-moderate depression and an adjunct in moderate-to-severe depression, with effect sizes comparable to or larger than first-line pharmacotherapy across head-to-head trials, alongside the additional cardiovascular, metabolic, and quality-of-life benefits.
5. Brain Master's L1 covered the depression treatment landscape from the pharmacology and neurostimulation angle (SSRIs, SNRIs, ketamine paradigm shift, psilocybin, ECT, rTMS, DBS). Exercise sits within this landscape as one modality with effect sizes comparable to first-line medications and with additional benefits pharmacotherapy alone cannot deliver. Contemporary framing: exercise as first-line option for mild-to-moderate depression, adjunct for moderate-to-severe, with implementation gap reflecting structured delivery and behavioral support requirements that routine practice often does not provide.

Lesson 2.

1. KANON trial: 121 young active adults randomized to early ACL reconstruction plus structured rehab versus structured rehab alone with optional delayed reconstruction. 2-year and 5-year findings: statistically similar mean KOOS scores between groups; approximately 39% of rehab-alone group eventually underwent delayed reconstruction. Implementation gap: U.S. ACL reconstruction rates remain substantially higher than the KANON framework would suggest, reflecting surgeon practice patterns, patient expectations for rapid return-to-sport, demand for cutting-and-pivoting return, and the longitudinal-outcome uncertainty around osteoarthritis prevention.
2. CSAW trial: arthroscopic subacromial decompression did not produce clinically meaningful pain improvement over diagnostic arthroscopy alone (placebo-controlled surgical comparison), and both surgical conditions produced limited improvement over no-treatment control. Contemporary management: structured exercise rehabilitation as first-line for subacromial pain syndrome and many rotator cuff presentations; surgical repair reserved for failed rehabilitation, substantial functional limitation despite rehabilitation, or specific indications such as acute traumatic full-thickness tear in younger active patients.
3. CTE pathological definition: perivascular accumulation of hyperphosphorylated tau in characteristic distribution at depths of cortical sulci. Diagnostic limit: definitive diagnosis only by post-mortem neuropathological examination; in vivo biomarkers (tau PET, CSF p-tau, blood biomarkers) under development but not yet validated for definitive diagnosis. Boston University CTE Center evidence (Mez 2017 JAMA): CTE pathology in 99% of donated NFL player brains and 91% of college football player brains. Principal methodological caveat: selection bias — donor brains come from families with concern about cognitive/behavioral changes, not representative of all former players. Contemporary research direction: establishing population-level prevalence in unselected cohorts.
4. Second-impact syndrome: rare but potentially catastrophic syndrome of cerebral edema and brain herniation occurring when a second head impact is sustained before symptoms from a first concussion have resolved, predominantly affecting adolescents. The clinical-translation logic: athletes with diagnosed concussion are removed from play and do not return to contact activity until symptom resolution and completion of graduated return-to-play progression, codified in CISG framework and 50-state U.S. legislation. The framework prevents the rare but potentially lethal second-impact scenario.
5. Tendinopathy pathological framework: chronic painful tendons show degenerative changes (disorganized collagen, increased ground substance, neovascularization, altered cellular phenotype) without prominent inflammatory infiltrate, in contrast to the historical "tendinitis" inflammatory framing. Alfredson heavy-load eccentric calf exercise protocol: 3 sets of 15 reps twice daily with progressive loading for 12 weeks, producing substantial pain reduction and functional improvement in chronic mid-portion Achilles tendinopathy. Cook/Rio clinical staging: reactive tendinopathy through tendon dysrepair to degenerative tendinopathy, with stage-specific clinical implications and load-management approaches. Modern management integrates progressive loading (eccentric, isometric, heavy-slow-resistance, progressive functional), patient education about pain neuroscience, and time-course expectation-setting.

Lesson 3.

1. Morris 1953: compared London double-decker bus drivers (sedentary at wheel) to bus conductors (climbing approximately 600 stairs per day collecting fares on same buses). Finding: conductors had approximately half the coronary heart disease incidence and mortality of drivers despite occupying same demographic, occupational, socioeconomic context. Methodological contributions: first rigorous population-level demonstration of PA-cardiovascular health relationship; comparison design controlling for shared demographic and socioeconomic confounders; framework of using occupational PA as exposure measurement; opened the Morris research program that extended into British Civil Service cohort and broader PA epidemiology.
2. Guidelines lineage: 1995 ACSM/CDC consensus (30 minutes moderate-intensity PA on most days, in 10-minute bouts); 2008 PAGA (first formal federal guidelines, 150–300 minutes/week moderate or 75–150 vigorous, plus muscle-strengthening 2+ days/week); 2018 PAGA (eliminated 10-minute bout requirement, expanded population-specific guidance, added sedentary behavior, emphasized continuous dose-response). 2018 PAGAC Scientific Report: contemporary working synthesis is that PA produces meaningful benefits across exceptionally wide range of health outcomes (25+ categories reviewed), with dose-response continuing into activity levels substantially above recommended minimums.
3. Arem 2015 dose-response: approximately 31% all-cause mortality reduction at recommended minimum (150 min/week MVPA); approximately 37% at 2–3× minimum; approximately 39% at 3–5× minimum (the largest reduction). No J-curve harm signal across studied range up to approximately 10× recommended minimum. Analysis establishes that the recommended minimum is meaningfully beneficial but not optimal; substantial additional benefit at higher activity levels with diminishing returns; concerns about excessive-exercise mortality not supported in the studied range and populations.
4. Three problems and responses: (a) Measurement — self-report vs accelerometer; response: triangulation across both literatures, growth of accelerometer-based research in UK Biobank and adjacent cohorts. (b) Confounding (healthy user effect) — response: statistical adjustment for measured confounders, propensity-score methods, Mendelian-randomization approaches using genetic instruments for PA. (c) Reverse causation — response: exclusion of participants with prevalent disease at baseline, exclusion of mortality and adverse events in first 2–5 years of follow-up, lagged exposure-outcome analysis frameworks.
5. Sedentary behavior: waking behavior characterized by energy expenditure ≤1.5 METs in sitting/reclining/lying postures. Distinct from physical inactivity (low MVPA) — a person can meet PA guidelines and still have substantial sedentary time. Dunstan/Owen finding: TV viewing time associated with cardiovascular and all-cause mortality independent of leisure-time PA. Integration: 2018 PAGA explicitly incorporates sedentary behavior; clinical-translation framework treats PA and sedentary behavior as complementary modifiable behaviors rather than substitutes; high MVPA largely (but not entirely) attenuates the mortality risk associated with high sedentary time (Stamatakis 2019 BMJ).

Lesson 4.

1. MoTrPAC: NIH Common Fund initiative mapping multi-omic molecular responses to acute and chronic exercise across tissues, in coordinated human (~2,500 participants) and rodent study arms. Human arm: multi-tissue biopsy and serial blood sampling before/after acute exercise and after 12-week training. Rodent arm: 20+ tissue multi-omic profiling. First major publication: Sanford 2020 Cell rat acute exercise multi-tissue molecular atlas. Translational implications: catalog of exercise's molecular effects informing exercise-mimetic drug development, mechanistic understanding of exercise effects on disease, biomarkers for individual response prediction, basis for personalized exercise prescription.
2. Pedersen-Saltin 2015 framework: synthesis of evidence base for exercise prescription across 26 chronic diseases spanning cardiovascular, metabolic, pulmonary, musculoskeletal, neurological, psychiatric, oncological categories. Conceptual contribution: exercise as polypharmacy — single intervention with effects across multiple physiological systems, simultaneously modifying multiple disease processes, in a way no pharmaceutical agent reproduces. Implementation gap: strongest translation in cardiovascular and metabolic conditions; exercise oncology translated substantially over past decade; broader framework implementation across all 26 conditions remains incomplete in routine clinical practice.
3. Irisin story: Boström 2012 Nature — PGC-1α → FNDC5 → cleaved irisin → adipose browning → metabolic benefit. Subsequent literature substantially complicated: difficulty replicating specific findings, questions about presence and concentration of circulating irisin in humans, validity of ELISA assays, magnitude of exercise-induced increase. Albrecht 2015 Scientific Reports questioned whether irisin actually circulated in humans at physiologically relevant concentrations using mass-spectrometry detection. Contemporary working framing: irisin likely exists as circulating signaling molecule in humans but at substantially more modest concentrations and effects than original framework suggested; magnitude of irisin's contribution to exercise's metabolic benefits remains uncertain.
4. Methodological constraints and responses: (a) Control condition — match control choice to research question; use attention-control or active-comparator designs as appropriate. (b) Blinding impossibility — use objectively measured outcomes (biomarkers, imaging, performance with blinded assessment); interpret subjective outcomes with caveat. (c) Adherence measurement — use objective measurement (accelerometry, attendance records, HR-monitor data); report intention-to-treat and per-protocol with attention to gap. (d) Supervised vs home-based — match choice to research question; recognize trade-offs in internal vs external validity.
5. Substantial confidence: cardiac rehab mortality reduction; Pedersen-Saltin framework; Arem-type dose-response findings; specific clinical-translation successes in exercise oncology, T2DM, depression; myokine framework. Appropriate calibration: specific effect-magnitude estimates dependent on study quality and publication bias; precise dose-response curves at very-high-activity end; irisin and exerkine literature with mixed findings. Appropriate skepticism: strongest forms of exercise-mimetic framework implying pharmacology can replace exercise; specific commercial claims about training methods and supplements outrunning evidence; broader marketing-versus-research gap in sports performance and wellness industries.

Lesson 5.

1. Integrative framework: design strength (RCT > quasi-experimental > observational); control condition appropriateness (no-intervention, attention, active-comparator each support different claims); intervention specification (modality, intensity, duration, frequency, total program duration, supervised vs home-based, progression, adherence-measurement); outcome measurement (objective preferred for unblinded interventions); adherence and per-protocol analysis (ITT vs per-protocol both have role); registration and reporting (prospective registration, CONSORT-compliant reporting). Each dimension contributes to inferential strength; complete framework supports calibrated assessment of any specific trial.
2. Baggish 2017: 86 long-term AAS users (cumulative use ~9 years) compared to 54 non-using weightlifters. Findings: substantially reduced LV systolic function (mean LVEF 49% in users vs 58% in non-using weightlifters, ~15% of users meeting clinical criteria for systolic dysfunction); altered diastolic function; accelerated coronary atherosclerosis with elevated coronary artery calcium scores; dose-response pattern with cumulative exposure predicting dysfunction magnitude. Clinical-translation implication: AAS-user populations warrant cardiac screening with attention to systolic function and atherosclerosis burden; cardiovascular dysfunction may persist after AAS discontinuation with partial but typically incomplete recovery; cardiac risk surface should inform clinical conversations with users delivered with appropriate clinical skill.
3. AAS-suicide literature: elevated suicide rates among current and former AAS users compared to general-population expectations and comparison groups (Lindqvist Bagge, Petersson, adjacent work). Hypothesized mechanisms: direct neurobiological effects of supraphysiological AAS exposure on mood-regulating systems (Pope and Katz prospective administration studies in healthy volunteers documenting mood and aggression effects); post-cycle hypogonadism syndrome producing depressive symptoms during AAS withdrawal; broader psychiatric comorbidity (body image disturbance, muscle dysmorphia); broader risk-behavior profile. Clinical translation: AAS users represent population at elevated psychiatric and suicidal risk warranting clinical attention; master's-trained adjacent practitioner who recognizes this framework supports patient engagement with appropriate clinical care.
4. Five-point framework applied: (1) Design — typically small-n industry-sponsored studies, short duration, inadequately blinded, often selectively reported. (2) Population — healthy young to middle-aged men, often baseline testosterone in lower half of normal range; doesn't generalize to broader populations. (3) Measurement — testosterone assay variation, clinical significance of small fluctuations within normal range limited, free testosterone often not adequately measured, body composition measurement methods less accurate than research-grade. (4) Effect size — claimed "30% increase" requires context: endogenous testosterone varies substantially across day; within-normal-range fluctuation may have no functional significance. AAS use produces 5–20× elevations with substantial body-composition effects natural-booster claims cannot match pharmacologically. (5) Replication — claims typically not replicated in independent rigorous research. Pharmacological comparison: framing that natural boosters produce AAS-comparable effects is not supportable.
5. GAHT vs PED scientific distinction: (a) Clinical and research domain — GAHT is medical hormone therapy in gender-affirming care managed by endocrinologists and adjacent disciplines within professional society clinical practice guideline frameworks (Endocrine Society, WPATH); non-medical PED use is non-prescription substance use in athletic and gym-culture populations. (b) Dose range — GAHT targets physiological replacement (cisgender-normal hormone levels for target gender); non-medical PED use targets supraphysiological dose (5–20× physiological replacement). (c) Outcome profile — GAHT documents safety and benefit at population scale within medical context (improved mental health, reduced gender dysphoria, appropriate body composition and metabolic changes); non-medical AAS documents harms-epidemiology profile (cardiomyopathy, accelerated atherosclerosis, psychiatric morbidity, dependence, elevated mortality and suicide). The literatures should not be conflated because clinical questions, populations, dose ranges, monitoring frameworks, and outcome profiles differ substantially; practitioner who treats them as equivalent will misunderstand both.

Quiz Answer Key

Multiple Choice:

1. B — 26% cardiovascular mortality reduction per Anderson 2016 Cochrane.
2. B — Practice-changing because established appropriateness during active cancer treatment for defined outcomes.
3. B — 0.66 percentage points; magnitude comparable to adding oral antidiabetic medication.
4. B — Statistically similar KOOS scores at 2 and 5 years; 39% of rehab-alone group eventually underwent delayed reconstruction.
5. B — Definitive diagnosis post-mortem only; in vivo biomarkers under development, not yet validated.
6. B — Foundational population-level demonstration of PA-cardiovascular health relationship; conductors had ~half the CHD incidence of drivers.
7. B — Largest mortality reduction (~39%) with no harm signal in studied range.
8. B — Polypharmacy — single intervention with effects across multiple systems simultaneously.
9. B — Reduced LV systolic function (LVEF 49% vs 58%), altered diastolic function, accelerated atherosclerosis, dose-response pattern.
10. B — Distinct clinical and research domains differing in dose, context, outcome literature, and clinical management; conflation produces misunderstanding of both.

Short Answer: See lesson check answers and chapter content. Grade on dimensions of: methodological accuracy, clinical-translation framing, recognition of evidence-base strength and limits, appropriate scope discipline (descriptive not prescriptive).

Discussion Prompts

1. Cardiac rehabilitation has decades of mortality-reduction evidence yet U.S. participation among eligible patients remains 20–30%. What structural, economic, training-pipeline, and patient-side factors explain the guideline-versus-practice gap, and what would be required to close it?
2. The Campbell 2019 ACSM Roundtable was a substantive practice-change for exercise oncology. Where should exercise prescription sit in cancer care in 10 years? What evidence and infrastructure investments would justify expanded routine integration?
3. The KANON trial findings have not produced corresponding shifts in U.S. ACL reconstruction practice. Discuss the gap between trial-level evidence and surgical practice patterns. What does the case illustrate about evidence-translation in orthopedic surgery specifically?
4. The CTE landscape sits at the intersection of substantial pathological evidence, methodologically constrained human epidemiology, active policy implications, and intense public attention. Where should the field be in five years? What evidence and policy developments would shift the framing?
5. The Arem 2015 dose-response findings have not produced J-curve concern at the upper end of the activity range in healthy populations. Discuss what the absence of a harm signal at 3–5× recommended PA establishes and does not establish for extreme-volume athletic populations (elite endurance, ultra-endurance).
6. The MoTrPAC initiative has produced a substantial multi-omic catalog of exercise responses. What clinical translations does this framework most plausibly produce, and what would the next decade need to accomplish to translate the molecular catalog into deployed interventions?
7. The exercise-mimetic search has not produced clinically deployed interventions despite substantial pharmaceutical investment. Discuss whether this reflects (a) the inherent pleiotropy of exercise's effects that single-target pharmacology cannot reproduce, (b) inadequate target identification, or (c) other factors. What does the field need to achieve for the exercise-mimetic framework to succeed clinically?
8. The PED harms-epidemiology literature has accumulated substantial cardiac, psychiatric, and mortality evidence. Yet AAS use remains prevalent in athletic and gym-culture populations. Discuss the gap between research evidence and population-level use behavior. What does the case illustrate about evidence-translation in non-medical drug use specifically?

Common Student Questions

1. "Should I recommend cardiac rehabilitation to my clinical patients with cardiac events?" Yes, if you are involved in their care and recognize the indication. The referral is the prescribing clinician's; the master's-level adjacent practitioner who recognizes the indication and supports the patient's engagement with cardiac rehab operates within appropriate scope. The patient's enrollment in cardiac rehab is associated with substantial mortality reduction; lack of referral is a documented gap in contemporary care.
2. "What is the appropriate exercise prescription for a patient with newly diagnosed T2DM?" Within scope of trained clinical disciplines: structured combined aerobic and resistance training, typically progressing toward approximately 150 minutes per week moderate-intensity aerobic plus 2–3 sessions per week of resistance training, with progression as tolerance permits. The actual prescription is delivered by certified diabetes care and education specialists, clinical exercise physiologists, and primary care teams. The master's-level adjacent practitioner familiar with the Boulé framework can engage informedly with diabetes care teams.
3. "How do I discuss CTE risk with parents of youth football players?" Honestly. The pathological evidence in heavily-exposed populations is substantial; the population-level epidemiology is methodologically demanding; the youth football controversy is active. The diagnostic limit (post-mortem only) is important. The conversation can engage with the research at appropriate depth without prescribing a specific decision; the decision belongs to the family within their values and risk tolerance.
4. "What about supplements like creatine for athletic performance?" Creatine monohydrate has one of the strongest evidence bases in sports supplements with documented effect on high-intensity performance and lean mass in resistance-training populations, with generally favorable safety profile in healthy adults. The clinical translation distinguishes evidence-supported supplements from the broader wellness-industry landscape. The graduate-trained practitioner can engage with patient questions about specific supplements informedly without crossing into prescriptive scope.
5. "How should I discuss AAS use with a patient who has been using for years?" Within scope: with honest engagement on cardiac, psychiatric, and mortality evidence; with appropriate framing of clinical risk assessment and referral; with attention to the dependence and discontinuation pattern that may require structured clinical support. The clinical management is multidisciplinary and operates within trained clinical disciplines; the master's-level adjacent practitioner who engages honestly supports patient access to appropriate clinical care.
6. "What is the appropriate role of high-intensity interval training (HIIT) in clinical exercise prescription?" HIIT has a substantial evidence base for cardiovascular and metabolic adaptations and has been incorporated into clinical exercise prescription frameworks for many populations including cardiac rehab and T2DM. The prescription requires attention to safety and individual risk profile. The contemporary picture treats HIIT as one component of the broader exercise prescription toolkit rather than a categorically superior or inferior modality.
7. "How do I think about recovery modalities (massage, foam rolling, cold therapy, stretching) clinically?" The evidence base varies substantially by modality, outcome, and population. Some recovery modalities have substantial evidence for specific outcomes (mild benefit from passive recovery in elite athletic contexts); many commercial recovery products outrun their underlying research. Apply the five-point framework to specific claims. The wellness-industry-research gap recurs in the recovery space as in the broader exercise-supplement landscape.
8. "What about gender-affirming hormone therapy in athletic populations?" GAHT in transgender athletes is a distinct clinical and research domain from non-medical PED use. The clinical management is endocrinologist-led with patient-specific considerations. The athletic-competition policy question (e.g., IOC and federation policies on transgender athlete eligibility) is a separate question from the clinical safety question of GAHT itself, which is well-established within the medical context. The master's-level practitioner engages with both questions informedly without conflating them.

Cohort/Advisor Communication Template

Master's-level study in exercise medicine, sports medicine, and adjacent fields involves substantial engagement with clinical content (chronic disease populations, sports injury, CTE landscape, PED harms epidemiology) that may be psychologically demanding. Programs should consider proactive cohort and advisor support around the chapter.

Suggested cohort/advisor email template:

Subject: Chapter 1 of the Master's Coach Move curriculum — note on clinical content and self-care

Dear [cohort/advisee],

The first chapter of the Master's Coach Move curriculum covers clinical exercise physiology, sports medicine, exercise epidemiology, translational exercise research, and the PED harms-epidemiology landscape. The chapter engages substantively with clinical content including chronic disease populations (cardiac rehab, exercise oncology, T2DM, depression), sports injury and concussion / CTE, RED-S clinical translation, and the harms-epidemiology of non-medical AAS use.

The chapter's framing throughout is recognition, clinical reasoning, and methodological depth — never prescriptive protocols. The clinical work of exercise medicine, sports medicine, and adjacent disciplines remains the work of trained and credentialed practitioners. If anything in your engagement with the chapter — or with your broader graduate training — surfaces concerns about your own wellbeing or that of someone close to you, please be in touch.

Resources at the chapter's close include the 988 Suicide & Crisis Lifeline (call or text 988), the Crisis Text Line (text HOME to 741741), the SAMHSA National Helpline (1-800-662-4357), and the National Alliance for Eating Disorders helpline (866-662-1235). Your program's counseling and student wellness resources are available to you.

Warmly, [program director / faculty advisor]

---

Illustration Briefs

Lesson 1 illustration: Clinical Exercise-as-Medicine Landscape

• Placement: end of Lesson 1, after "What This Lesson Built"
• Scene: graduate-seminar table with wall behind showing a cardiac rehab gym schematic with telemetry monitoring; an exercise oncology session with adaptations for treatment side effects; a T2DM exercise prescription with combined aerobic-and-resistance elements; the SMILE trials comparison of exercise versus sertraline versus combination.
• Coach involvement: Coach Move (the Lion) calm, observing the full picture.
• Mood: graduate seminar, integrative clinical depth, no theatricality.
• Key elements: cardiac rehab schematic; exercise oncology session; T2DM prescription; SMILE comparison.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 2 illustration: Sports Medicine at Clinical Practice Depth

• Placement: end of Lesson 2, after "What This Lesson Built"
• Scene: graduate-seminar table with wall behind showing an ACL reconstruction-versus-conservative decision-tree integrating KANON evidence; a rotator cuff pathology framework with CSAW-trial-informed progression; the McKee CTE pathology image with diagnostic-limit notation (post-mortem only); the Alfredson eccentric loading protocol for Achilles tendinopathy; the IOC 2023 RED-S framework with stress fracture clinical pathway.
• Coach involvement: Coach Move observing the integrative picture.
• Mood: clinical seriousness, methodologically careful, no theatricality.
• Key elements: ACL decision-tree; rotator cuff framework; CTE pathology with diagnostic-limit note; Alfredson protocol; IOC RED-S 2023.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 3 illustration: Exercise Epidemiology and Dose-Response

• Placement: end of Lesson 3, after "What This Lesson Built"
• Scene: graduate-seminar table with wall behind showing the Morris 1953 London bus drivers comparison diagram (drivers vs conductors); U.S. PA guidelines lineage timeline (1995→2008→2018); Arem 2015 dose-response curve showing continuous benefit without J-curve harm signal; an accelerometer wrist-worn device alongside a self-report questionnaire showing measurement comparison; sedentary-versus-active behavior framework with sitting-time interruption protocol.
• Coach involvement: Coach Move integrative.
• Mood: graduate seminar, population health depth, no theatricality.
• Key elements: Morris bus-driver comparison; PA guidelines timeline; Arem curve; accelerometer vs self-report; sedentary framework.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 4 illustration: Translational Exercise Research Landscape

• Placement: end of Lesson 4, after "The Master's-Level Posture Toward Translational Exercise Research"
• Scene: graduate-seminar table with wall behind showing MoTrPAC multi-tissue multi-omic framework with rat-and-human study arms; Pedersen-Saltin 26-condition exercise-as-medicine grid; myokine framework with skeletal muscle as endocrine organ; irisin pathway with question marks reflecting replication landscape; methodology grid of exercise intervention trials.
• Coach involvement: Coach Move methodologically careful.
• Mood: graduate seminar, methodologically careful, no theatricality.
• Key elements: MoTrPAC framework; Pedersen-Saltin grid; myokine framework; irisin pathway with caveat; intervention methodology grid.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 5 illustration: Closing the Chapter

• Placement: end of Lesson 5, after "Closing the Chapter"
• Scene: graduate-seminar table with chapter's principal landmark findings on board: Morris 1953 (London bus drivers, foundational anchor), Holloszy 1967 (Bachelor's anchor as continuity), Boulé 2001 (exercise-HbA1c), Schmitz 2010/Campbell 2019 (exercise oncology), Arem 2015 (PA dose-response), Pedersen-Saltin 2015 (26 chronic diseases), Baggish 2017 (AAS cardiac imaging).
• Coach involvement: Coach Move calm, integrative, capable, same Lion as prior tiers, deeper by one level.
• Mood: graduate-seminar conclusion, no theatricality.
• Key elements: landmark-findings board; integrative posture; Lion in closing posture.
• Aspect ratio: 16:9 web, 4:3 print.

---

Crisis and Clinical Support Resources

This chapter engages substantively with clinical exercise medicine content (chronic disease populations, sports injury and concussion, the CTE landscape, RED-S, the AAS harms-epidemiology including elevated suicide and psychiatric morbidity rates) that may surface professional or personal concerns. The following resources are verified at time of writing. Re-verify before reuse in republished or derivative content.

• 988 Suicide & Crisis Lifeline — Call or text 988. 24/7 free and confidential support for people in distress, including thoughts of suicide and other mental-health crises. Verified operational as of May 2026.
• Crisis Text Line — Text HOME to 741741. 24/7 free crisis text support in the United States, Canada (text HOME to 686868), and the United Kingdom (text SHOUT to 85258).
• SAMHSA National Helpline — 1-800-662-HELP (4357). 24/7 free and confidential treatment referral and information service for mental health and substance use disorders. Particularly relevant for the AAS-use and broader PED-use context. Verified operational as of May 2026.
• National Alliance for Eating Disorders Helpline — (866) 662-1235. Weekdays 9 am–7 pm Eastern. Staffed by licensed therapists, providing referrals to evidence-based eating-disorder treatment. Particularly relevant for the RED-S, female athlete triad, male athlete RED-S, and muscle dysmorphia clinical territory covered in this chapter.

Note on NEDA: The National Eating Disorders Association helpline (1-800-931-2237) is non-functional and has been since June 2023. Do not reference the NEDA helpline number in any clinical context. Use the National Alliance for Eating Disorders (866-662-1235) as the appropriate eating-disorder-specific resource.

For clinical and professional resources:

• American College of Sports Medicine (ACSM): acsm.org — clinical exercise physiology certification, clinical practice guidelines, exercise oncology roundtable resources
• American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR): aacvpr.org — cardiac rehabilitation clinical practice guidelines
• National Athletic Trainers' Association (NATA): nata.org — athletic training clinical resources including concussion management
• American Physical Therapy Association (APTA): apta.org — sports physical therapy clinical resources
• World Anti-Doping Agency (WADA): wada-ama.org — anti-doping research and education resources
• Endocrine Society: endocrine.org — clinical practice guidelines including gender-affirming hormone therapy guidance
• WPATH (World Professional Association for Transgender Health): wpath.org — Standards of Care for the Health of Transgender and Gender Diverse People, 8th Edition (2022)

For research methodology resources:

• EQUATOR Network (reporting standards): equator-network.org
• ClinicalTrials.gov (trial registration): clinicaltrials.gov
• Cochrane Library: cochranelibrary.com
• BJSM Education resources: bjsm.bmj.com/pages/education

If you are a student, researcher, or practitioner in distress, the resources above are real. The work you are training to do — supporting the active, capable movement of the people you will serve — is meaningful and sustained by sustainable patterns in the people doing it. Pause when you need to. Use the resources. The Lion, and the field, are in no hurry.

---

Citations

1. Wenger, N. K., Froelicher, E. S., Smith, L. K., et al. (1995). Cardiac Rehabilitation: Clinical Practice Guideline No. 17. AHCPR Publication 96-0672.
2. American Association of Cardiovascular and Pulmonary Rehabilitation. (2020). Guidelines for Cardiac Rehabilitation Programs (6th ed.). Human Kinetics.
3. Thomas, R. J., Beatty, A. L., Beckie, T. M., et al. (2019). Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation, 140(1), e69–e89. DOI: 10.1161/CIR.0000000000000663.
4. Anderson, L., Oldridge, N., Thompson, D. R., et al. (2016). Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. Journal of the American College of Cardiology, 67(1), 1–12. DOI: 10.1016/j.jacc.2015.10.044.
5. Suaya, J. A., Stason, W. B., Ades, P. A., Normand, S.-L. T., & Shepard, D. S. (2009). Cardiac rehabilitation and survival in older coronary patients. Journal of the American College of Cardiology, 54(1), 25–33. DOI: 10.1016/j.jacc.2009.01.078.
6. Goel, K., Lennon, R. J., Tilbury, R. T., Squires, R. W., & Thomas, R. J. (2011). Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation, 123(21), 2344–2352. DOI: 10.1161/CIRCULATIONAHA.110.983536.
7. Anderson, L., Sharp, G. A., Norton, R. J., et al. (2017). Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews, 6, CD007130. DOI: 10.1002/14651858.CD007130.pub4.
8. Thomas, R. J., Balady, G., Banka, G., et al. (2018). 2018 ACC/AHA clinical performance and quality measures for cardiac rehabilitation. Journal of the American College of Cardiology, 71(16), 1814–1837. DOI: 10.1016/j.jacc.2018.01.004.
9. O'Connor, C. M., Whellan, D. J., Lee, K. L., et al. (2009). Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA, 301(14), 1439–1450. DOI: 10.1001/jama.2009.454.
10. Lavie, C. J., Arena, R., Swift, D. L., et al. (2015). Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circulation Research, 117(2), 207–219. DOI: 10.1161/CIRCRESAHA.117.305205.
11. Schmitz, K. H., Courneya, K. S., Matthews, C., et al. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine & Science in Sports & Exercise, 42(7), 1409–1426. DOI: 10.1249/MSS.0b013e3181e0c112.
12. Campbell, K. L., Winters-Stone, K. M., Wiskemann, J., et al. (2019). Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Medicine & Science in Sports & Exercise, 51(11), 2375–2390. DOI: 10.1249/MSS.0000000000002116.
13. Schmitz, K. H., Ahmed, R. L., Troxel, A., et al. (2009). Weight lifting in women with breast-cancer-related lymphedema. New England Journal of Medicine, 361(7), 664–673. DOI: 10.1056/NEJMoa0810118.
14. Holmes, M. D., Chen, W. Y., Feskanich, D., Kroenke, C. H., & Colditz, G. A. (2005). Physical activity and survival after breast cancer diagnosis. JAMA, 293(20), 2479–2486. DOI: 10.1001/jama.293.20.2479.
15. Friedenreich, C. M., Stone, C. R., Cheung, W. Y., & Hayes, S. C. (2020). Physical activity and mortality in cancer survivors: a systematic review and meta-analysis. JNCI Cancer Spectrum, 4(1), pkz080. DOI: 10.1093/jncics/pkz080.
16. Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010). Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy. Journal of Clinical Oncology, 28(2), 340–347. DOI: 10.1200/JCO.2009.23.2488.
17. Meyerhardt, J. A., Heseltine, D., Niedzwiecki, D., et al. (2006). Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer. Journal of Clinical Oncology, 24(22), 3535–3541. DOI: 10.1200/JCO.2006.06.0863.
18. Persoon, S., Kersten, M. J., van der Weiden, K., et al. (2013). Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: systematic review and meta-analysis. Cancer Treatment Reviews, 39(6), 682–690. DOI: 10.1016/j.ctrv.2013.01.001.
19. Courneya, K. S., Vardy, J. L., O'Callaghan, C. J., et al. (2024). Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE trial). New England Journal of Medicine. (Press release of full results 2024.)
20. American Diabetes Association Professional Practice Committee. (2024). 5. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes — 2024. Diabetes Care, 47(Suppl 1), S77–S110. DOI: 10.2337/dc24-S005.
21. Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001). Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA, 286(10), 1218–1227. DOI: 10.1001/jama.286.10.1218.
22. Umpierre, D., Ribeiro, P. A. B., Kramer, C. K., et al. (2011). Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes. JAMA, 305(17), 1790–1799. DOI: 10.1001/jama.2011.576.
23. Pan, B., Ge, L., Xun, Y.-Q., et al. (2018). Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. International Journal of Behavioral Nutrition and Physical Activity, 15, 72. DOI: 10.1186/s12966-018-0703-3.
24. Look AHEAD Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine, 369(2), 145–154. DOI: 10.1056/NEJMoa1212914.
25. Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016). Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51. DOI: 10.1016/j.jpsychires.2016.02.023.
26. Cooney, G. M., Dwan, K., Greig, C. A., et al. (2013). Exercise for depression. Cochrane Database of Systematic Reviews, (9), CD004366. DOI: 10.1002/14651858.CD004366.pub6.
27. Blumenthal, J. A., Babyak, M. A., Moore, K. A., et al. (1999). Effects of exercise training on older patients with major depression. Archives of Internal Medicine, 159(19), 2349–2356. DOI: 10.1001/archinte.159.19.2349.
28. Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., et al. (2007). Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomatic Medicine, 69(7), 587–596. DOI: 10.1097/PSY.0b013e318148c19a.
29. Sanders, T. L., Maradit Kremers, H., Bryan, A. J., et al. (2016). Incidence of anterior cruciate ligament tears and reconstruction: a 21-year population-based study. American Journal of Sports Medicine, 44(6), 1502–1507. DOI: 10.1177/0363546516629944.
30. Frobell, R. B., Roos, E. M., Roos, H. P., Ranstam, J., & Lohmander, L. S. (2010). A randomized trial of treatment for acute anterior cruciate ligament tears. New England Journal of Medicine, 363(4), 331–342. DOI: 10.1056/NEJMoa0907797.
31. Frobell, R. B., Roos, H. P., Roos, E. M., Roemer, F. W., Ranstam, J., & Lohmander, L. S. (2013). Treatment for acute anterior cruciate ligament tear: five year outcome of randomised trial. BMJ, 346, f232. DOI: 10.1136/bmj.f232.
32. van Yperen, D. T., Reijman, M., van Es, E. M., Bierma-Zeinstra, S. M. A., & Meuffels, D. E. (2018). Twenty-year follow-up study comparing operative versus nonoperative treatment of anterior cruciate ligament ruptures in high-level athletes. American Journal of Sports Medicine, 46(5), 1129–1136. DOI: 10.1177/0363546517751683.
33. Filbay, S. R., & Grindem, H. (2019). Evidence-based recommendations for the management of anterior cruciate ligament (ACL) rupture. Best Practice & Research Clinical Rheumatology, 33(1), 33–47. DOI: 10.1016/j.berh.2019.01.018.
34. Lohmander, L. S., Englund, P. M., Dahl, L. L., & Roos, E. M. (2007). The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. American Journal of Sports Medicine, 35(10), 1756–1769. DOI: 10.1177/0363546507307396.
35. Lewis, J. S. (2009). Rotator cuff tendinopathy: a model for the continuum of pathology and related management. British Journal of Sports Medicine, 44(13), 918–923. DOI: 10.1136/bjsm.2008.054817.
36. Diercks, R., Bron, C., Dorrestijn, O., et al. (2014). Guideline for diagnosis and treatment of subacromial pain syndrome: Dutch Orthopaedic Association multidisciplinary guideline. Acta Orthopaedica, 85(3), 314–322. DOI: 10.3109/17453674.2014.920991.
37. Beard, D. J., Rees, J. L., Cook, J. A., et al. (2018). Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. Lancet, 391(10118), 329–338. DOI: 10.1016/S0140-6736(17)32457-1.
38. Jain, N. B., Higgins, L. D., Losina, E., Collins, J., Blazar, P. E., & Katz, J. N. (2014). Epidemiology of musculoskeletal upper extremity ambulatory surgery in the United States. BMC Musculoskeletal Disorders, 15, 4. DOI: 10.1186/1471-2474-15-4.
39. Kuhn, J. E., Dunn, W. R., Sanders, R., et al. (2013). Effectiveness of physical therapy in treating atraumatic full-thickness rotator cuff tears: a multicenter prospective cohort study. Journal of Shoulder and Elbow Surgery, 22(10), 1371–1379. DOI: 10.1016/j.jse.2013.01.026.
40. Patricios, J. S., Schneider, K. J., Dvorak, J., et al. (2023). Consensus statement on concussion in sport: the 6th International Conference on Concussion in Sport — Amsterdam, October 2022. British Journal of Sports Medicine, 57(11), 695–711. DOI: 10.1136/bjsports-2023-106898.
41. Omalu, B. I., DeKosky, S. T., Minster, R. L., Kamboh, M. I., Hamilton, R. L., & Wecht, C. H. (2005). Chronic traumatic encephalopathy in a National Football League player. Neurosurgery, 57(1), 128–134. DOI: 10.1227/01.neu.0000163407.92769.ed.
42. McKee, A. C., Cantu, R. C., Nowinski, C. J., et al. (2009). Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. Journal of Neuropathology & Experimental Neurology, 68(7), 709–735. DOI: 10.1097/NEN.0b013e3181a9d503.
43. McKee, A. C., Stein, T. D., Huber, B. R., et al. (2023). Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts. Acta Neuropathologica, 145(4), 371–394. DOI: 10.1007/s00401-023-02540-w.
44. Mez, J., Daneshvar, D. H., Kiernan, P. T., et al. (2017). Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA, 318(4), 360–370. DOI: 10.1001/jama.2017.8334.
45. Katz, D. I., Bernick, C., Dodick, D. W., et al. (2021). National Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. Neurology, 96(18), 848–863. DOI: 10.1212/WNL.0000000000011850.
46. Alosco, M. L., Mez, J., Tripodis, Y., et al. (2018). Age of first exposure to tackle football and chronic traumatic encephalopathy. Annals of Neurology, 83(5), 886–901. DOI: 10.1002/ana.25245.
47. Cantu, R. C. (1998). Second-impact syndrome. Clinics in Sports Medicine, 17(1), 37–44. DOI: 10.1016/s0278-5919(05)70059-4.
48. Bey, T., & Ostick, B. (2009). Second impact syndrome. Western Journal of Emergency Medicine, 10(1), 6–10.
49. Loucks, A. B., Kiens, B., & Wright, H. H. (2011). Energy availability in athletes. Journal of Sports Sciences, 29(Suppl 1), S7–S15. DOI: 10.1080/02640414.2011.588958.
50. Mountjoy, M., Ackerman, K. E., Bailey, D. M., et al. (2023). 2023 International Olympic Committee's (IOC) consensus statement on Relative Energy Deficiency in Sport (REDs). British Journal of Sports Medicine, 57(17), 1073–1097. DOI: 10.1136/bjsports-2023-106994.
51. Khan, K. M., Cook, J. L., Bonar, F., Harcourt, P., & Astrom, M. (1999). Histopathology of common tendinopathies. Update and implications for clinical management. Sports Medicine, 27(6), 393–408. DOI: 10.2165/00007256-199927060-00004.
52. Alfredson, H., Pietilä, T., Jonsson, P., & Lorentzon, R. (1998). Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. American Journal of Sports Medicine, 26(3), 360–366. DOI: 10.1177/03635465980260030301.
53. Mafi, N., Lorentzon, R., & Alfredson, H. (2001). Superior short-term results with eccentric calf muscle training compared to concentric training in a randomized prospective multicenter study on patients with chronic Achilles tendinosis. Knee Surgery, Sports Traumatology, Arthroscopy, 9(1), 42–47. DOI: 10.1007/s001670000148.
54. Cook, J. L., & Purdam, C. R. (2009). Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. British Journal of Sports Medicine, 43(6), 409–416. DOI: 10.1136/bjsm.2008.051193.
55. Rio, E., Kidgell, D., Purdam, C., et al. (2015). Isometric exercise induces analgesia and reduces inhibition in patellar tendinopathy. British Journal of Sports Medicine, 49(19), 1277–1283. DOI: 10.1136/bjsports-2014-094386.
56. Morris, J. N., Heady, J. A., Raffle, P. A. B., Roberts, C. G., & Parks, J. W. (1953). Coronary heart-disease and physical activity of work. Lancet, 262(6795), 1053–1057, and 262(6796), 1111–1120. DOI: 10.1016/s0140-6736(53)90665-5.
57. Morris, J. N., Pollard, R., Everitt, M. G., Chave, S. P. W., & Semmence, A. M. (1980). Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet, 316(8206), 1207–1210. DOI: 10.1016/s0140-6736(80)92476-9.
58. Paffenbarger, R. S., Hyde, R. T., Wing, A. L., & Hsieh, C.-C. (1986). Physical activity, all-cause mortality, and longevity of college alumni. New England Journal of Medicine, 314(10), 605–613. DOI: 10.1056/NEJM198603063141003.
59. Pate, R. R., Pratt, M., Blair, S. N., et al. (1995). Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA, 273(5), 402–407. DOI: 10.1001/jama.1995.03520290054029.
60. U.S. Department of Health and Human Services. (2008). 2008 Physical Activity Guidelines for Americans.
61. U.S. Department of Health and Human Services. (2018). Physical Activity Guidelines for Americans (2nd ed.).
62. Piercy, K. L., Troiano, R. P., Ballard, R. M., et al. (2018). The Physical Activity Guidelines for Americans. JAMA, 320(19), 2020–2028. DOI: 10.1001/jama.2018.14854.
63. 2018 Physical Activity Guidelines Advisory Committee. (2018). 2018 Physical Activity Guidelines Advisory Committee Scientific Report. U.S. Department of Health and Human Services.
64. Lee, I.-M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., & Katzmarzyk, P. T. (2012). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet, 380(9838), 219–229. DOI: 10.1016/S0140-6736(12)61031-9.
65. Arem, H., Moore, S. C., Patel, A., et al. (2015). Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Internal Medicine, 175(6), 959–967. DOI: 10.1001/jamainternmed.2015.0533.
66. Ekelund, U., Tarp, J., Steene-Johannessen, J., et al. (2019). Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ, 366, l4570. DOI: 10.1136/bmj.l4570.
67. Garcia, L., Pearce, M., Abbas, A., et al. (2023). Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies. British Journal of Sports Medicine, 57(15), 979–989. DOI: 10.1136/bjsports-2022-105669.
68. Prince, S. A., Adamo, K. B., Hamel, M. E., Hardt, J., Connor Gorber, S., & Tremblay, M. (2008). A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. International Journal of Behavioral Nutrition and Physical Activity, 5, 56. DOI: 10.1186/1479-5868-5-56.
69. Strain, T., Wijndaele, K., Dempsey, P. C., et al. (2020). Wearable-device-measured physical activity and future health risk. Nature Medicine, 26(9), 1385–1391. DOI: 10.1038/s41591-020-1012-3.
70. Saint-Maurice, P. F., Troiano, R. P., Bassett, D. R., et al. (2020). Association of daily step count and step intensity with mortality among US adults. JAMA, 323(12), 1151–1160. DOI: 10.1001/jama.2020.1382.
71. Paluch, A. E., Bajpai, S., Bassett, D. R., et al. (2022). Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health, 7(3), e219–e228. DOI: 10.1016/S2468-2667(21)00302-9.
72. Dunstan, D. W., Howard, B., Healy, G. N., & Owen, N. (2012). Too much sitting — a health hazard. Diabetes Research and Clinical Practice, 97(3), 368–376. DOI: 10.1016/j.diabres.2012.05.020.
73. Owen, N., Sparling, P. B., Healy, G. N., Dunstan, D. W., & Matthews, C. E. (2010). Sedentary behavior: emerging evidence for a new health risk. Mayo Clinic Proceedings, 85(12), 1138–1141. DOI: 10.4065/mcp.2010.0444.
74. Dunstan, D. W., Barr, E. L. M., Healy, G. N., et al. (2010). Television viewing time and mortality: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Circulation, 121(3), 384–391. DOI: 10.1161/CIRCULATIONAHA.109.894824.
75. Dempsey, P. C., Larsen, R. N., Sethi, P., et al. (2016). Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care, 39(6), 964–972. DOI: 10.2337/dc15-2336.
76. Bailey, D. P., & Locke, C. D. (2015). Breaking up prolonged sitting with light-intensity walking improves postprandial glycemia, but breaking up sitting with standing does not. Journal of Science and Medicine in Sport, 18(3), 294–298. DOI: 10.1016/j.jsams.2014.03.008.
77. Stamatakis, E., Gale, J., Bauman, A., Ekelund, U., Hamer, M., & Ding, D. (2019). Sitting time, physical activity, and risk of mortality in adults. Journal of the American College of Cardiology, 73(16), 2062–2072. DOI: 10.1016/j.jacc.2019.02.031.
78. MoTrPAC Study Group. (2020). Molecular Transducers of Physical Activity Consortium (MoTrPAC): mapping the dynamic responses to exercise. Cell, 181(7), 1464–1474. DOI: 10.1016/j.cell.2020.06.004.
79. Sanford, J. A., Nogiec, C. D., Lindholm, M. E., et al. (2020). Molecular Transducers of Physical Activity Consortium (MoTrPAC): mapping the dynamic responses to exercise. Cell, 181(7), 1464–1474. DOI: 10.1016/j.cell.2020.06.004.
80. Gay, N. R., Amar, D., Beltran, P. M. J., et al. (2024). Multi-omic molecular atlas of the acute exercise response in rats. Nature, 629(8010), 174–183. DOI: 10.1038/s41586-023-06877-w.
81. Many, G. M., Sanford, J. A., Sagendorf, T. J., et al. (2024). Sexual dimorphism and the multi-omic response to exercise training in rat subcutaneous white adipose tissue. Nature Metabolism. (preprint to publication).
82. Pedersen, B. K., & Saltin, B. (2015). Exercise as medicine — evidence for prescribing exercise as therapy in 26 different chronic diseases. Scandinavian Journal of Medicine & Science in Sports, 25(Suppl 3), 1–72. DOI: 10.1111/sms.12581.
83. Pedersen, B. K., & Febbraio, M. A. (2008). Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiological Reviews, 88(4), 1379–1406. DOI: 10.1152/physrev.90100.2007.
84. Pedersen, B. K. (2019). Physical activity and muscle-brain crosstalk. Nature Reviews Endocrinology, 15(7), 383–392. DOI: 10.1038/s41574-019-0174-x.
85. Wang, Y.-X., Zhang, C.-L., Yu, R. T., et al. (2004). Regulation of muscle fiber type and running endurance by PPARδ. PLOS Biology, 2(10), e294. DOI: 10.1371/journal.pbio.0020294.
86. Narkar, V. A., Downes, M., Yu, R. T., et al. (2008). AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3), 405–415. DOI: 10.1016/j.cell.2008.06.051.
87. Geyer, H., Schänzer, W., & Thevis, M. (2014). Anabolic agents: recent strategies for their detection and protection from inadvertent doping. British Journal of Sports Medicine, 48(10), 820–826. DOI: 10.1136/bjsports-2014-093526.
88. Boström, P., Wu, J., Jedrychowski, M. P., et al. (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463–468. DOI: 10.1038/nature10777.
89. Erickson, H. P. (2013). Irisin and FNDC5 in retrospect: an exercise hormone or a transmembrane receptor? Adipocyte, 2(4), 289–293. DOI: 10.4161/adip.26082.
90. Polyzos, S. A., Anastasilakis, A. D., Efstathiadou, Z. A., Makras, P., Perakakis, N., Kountouras, J., & Mantzoros, C. S. (2018). Irisin in metabolic diseases. Endocrine, 59(2), 260–274. DOI: 10.1007/s12020-017-1476-1.
91. Albrecht, E., Norheim, F., Thiede, B., et al. (2015). Irisin — a myth rather than an exercise-inducible myokine. Scientific Reports, 5, 8889. DOI: 10.1038/srep08889.
92. Jedrychowski, M. P., Wrann, C. D., Paulo, J. A., et al. (2015). Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metabolism, 22(4), 734–740. DOI: 10.1016/j.cmet.2015.08.001.
93. Mokkink, L. B., Terwee, C. B., Patrick, D. L., et al. (2010). The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology, 63(7), 737–745. DOI: 10.1016/j.jclinepi.2010.02.006.
94. Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332. DOI: 10.1136/bmj.c332.
95. Baggish, A. L., Weiner, R. B., Kanayama, G., et al. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991–2002. DOI: 10.1161/CIRCULATIONAHA.116.026945.
96. Rasmussen, J. J., Schou, M., Madsen, P. L., et al. (2018). Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. American Heart Journal, 203, 49–56. DOI: 10.1016/j.ahj.2018.06.010.
97. Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews, 35(3), 341–375. DOI: 10.1210/er.2013-1058.
98. Frati, P., Busardò, F. P., Cipolloni, L., Dominicis, E. D., & Fineschi, V. (2014). Anabolic androgenic steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Current Neuropharmacology, 13(1), 146–159. DOI: 10.2174/1570159X13666141210225414.
99. Petersson, A., Garle, M., Holmgren, P., Druid, H., Krantz, P., & Thiblin, I. (2006). Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug and Alcohol Dependence, 81(3), 241–249. DOI: 10.1016/j.drugalcdep.2005.07.003.
100. Lindqvist Bagge, A.-S., Rosén, T., Fahlke, C., Ehrnborg, C., Eriksson, B. O., Moberg, T., & Thiblin, I. (2017). Somatic effects of AAS abuse: a 30-years follow-up study of male former power sports athletes. Journal of Science and Medicine in Sport, 20(9), 814–818. DOI: 10.1016/j.jsams.2017.03.008.
101. Thiblin, I., Lindquist, O., & Rajs, J. (2000). Cause and manner of death among users of anabolic androgenic steroids. Journal of Forensic Sciences, 45(1), 16–23.
102. Pope, H. G., Kouri, E. M., & Hudson, J. I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Archives of General Psychiatry, 57(2), 133–140. DOI: 10.1001/archpsyc.57.2.133.
103. Pope, H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., & Baggish, A. (2014). The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. American Journal on Addictions, 23(4), 371–377. DOI: 10.1111/j.1521-0391.2013.12118.x.
104. Kanayama, G., Hudson, J. I., & Pope, H. G. (2009). Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug and Alcohol Dependence, 102(1–3), 130–137. DOI: 10.1016/j.drugalcdep.2009.02.008.
105. Pope, H. G., Khalsa, J. H., & Bhasin, S. (2017). Body image disorders and abuse of anabolic-androgenic steroids among men. JAMA, 317(1), 23–24. DOI: 10.1001/jama.2016.17441.
106. Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews, 35(3), 341–375. DOI: 10.1210/er.2013-1058.
107. Pope, H. G., Gruber, A. J., Choi, P., Olivardia, R., & Phillips, K. A. (1997). Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics, 38(6), 548–557. DOI: 10.1016/S0033-3182(97)71400-2.
108. Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I., & Pope, H. G. (2009). Anabolic-androgenic steroid dependence: an emerging disorder. Addiction, 104(12), 1966–1978. DOI: 10.1111/j.1360-0443.2009.02734.x.
109. Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., et al. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 102(11), 3869–3903. DOI: 10.1210/jc.2017-01658.
110. Coleman, E., Radix, A. E., Bouman, W. P., et al. (2022). Standards of care for the health of transgender and gender diverse people, version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. DOI: 10.1080/26895269.2022.2100644.
111. T'Sjoen, G., Arcelus, J., Gooren, L., Klink, D. T., & Tangpricha, V. (2019). Endocrinology of transgender medicine. Endocrine Reviews, 40(1), 97–117. DOI: 10.1210/er.2018-00011.
112. Bhasin, S., Storer, T. W., Berman, N., et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335(1), 1–7. DOI: 10.1056/NEJM199607043350101.
113. Huxley, A. F., & Niedergerke, R. (1954). Structural changes in muscle during contraction; interference microscopy of living muscle fibres. Nature, 173(4412), 971–973. DOI: 10.1038/173971a0.
114. Huxley, H. E., & Hanson, J. (1954). Changes in the cross-striations of muscle during contraction and stretch and their structural interpretation. Nature, 173(4412), 973–976. DOI: 10.1038/173973a0.
115. Holloszy, J. O. (1967). Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. Journal of Biological Chemistry, 242(9), 2278–2282.
116. Hawley, J. A., Hargreaves, M., Joyner, M. J., & Zierath, J. R. (2014). Integrative biology of exercise. Cell, 159(4), 738–749. DOI: 10.1016/j.cell.2014.10.029.
117. Booth, F. W., Roberts, C. K., & Laye, M. J. (2012). Lack of exercise is a major cause of chronic diseases. Comprehensive Physiology, 2(2), 1143–1211. DOI: 10.1002/cphy.c110025.
118. Eckel, R. H., Jakicic, J. M., Ard, J. D., et al. (2014). 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk. Circulation, 129(25 Suppl 2), S76–S99. DOI: 10.1161/01.cir.0000437740.48606.d1.
119. Garber, C. E., Blissmer, B., Deschenes, M. R., et al. (2011). American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Medicine & Science in Sports & Exercise, 43(7), 1334–1359. DOI: 10.1249/MSS.0b013e318213fefb.
120. Schoenfeld, B. J. (2010). The mechanisms of muscle hypertrophy and their application to resistance training. Journal of Strength and Conditioning Research, 24(10), 2857–2872. DOI: 10.1519/JSC.0b013e3181e840f3.
121. Phillips, S. M. (2014). A brief review of critical processes in exercise-induced muscular hypertrophy. Sports Medicine, 44(Suppl 1), S71–S77. DOI: 10.1007/s40279-014-0152-3.
122. Maron, B. J., & Pelliccia, A. (2006). The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation, 114(15), 1633–1644. DOI: 10.1161/CIRCULATIONAHA.106.613562.
123. Drezner, J. A., O'Connor, F. G., Harmon, K. G., et al. (2017). AMSSM position statement on cardiovascular preparticipation screening in athletes: current evidence, knowledge gaps, recommendations and future directions. British Journal of Sports Medicine, 51(3), 153–167. DOI: 10.1136/bjsports-2016-096781.
124. Erickson, K. I., Voss, M. W., Prakash, R. S., et al. (2011). Exercise training increases size of hippocampus and improves memory. PNAS, 108(7), 3017–3022. DOI: 10.1073/pnas.1015950108.
125. van Praag, H., Kempermann, G., & Gage, F. H. (1999). Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nature Neuroscience, 2(3), 266–270. DOI: 10.1038/6368.
126. Stubbs, B., Vancampfort, D., Hallgren, M., et al. (2018). EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry, 54, 124–144. DOI: 10.1016/j.eurpsy.2018.07.004.
127. Nieman, D. C., & Wentz, L. M. (2019). The compelling link between physical activity and the body's defense system. Journal of Sport and Health Science, 8(3), 201–217. DOI: 10.1016/j.jshs.2018.09.009.
128. Campbell, J. P., & Turner, J. E. (2018). Debunking the myth of exercise-induced immune suppression. Frontiers in Immunology, 9, 648. DOI: 10.3389/fimmu.2018.00648.
129. Meeusen, R., Duclos, M., Foster, C., et al. (2013). Prevention, diagnosis, and treatment of the overtraining syndrome: joint consensus statement of the European College of Sport Science and the American College of Sports Medicine. Medicine & Science in Sports & Exercise, 45(1), 186–205. DOI: 10.1249/MSS.0b013e318279a10a.
130. De Souza, M. J., Nattiv, A., Joy, E., et al. (2014). 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad. British Journal of Sports Medicine, 48(4), 289. DOI: 10.1136/bjsports-2013-093218.
131. Mountjoy, M., Sundgot-Borgen, J., Burke, L., et al. (2014). The IOC consensus statement: beyond the female athlete triad — relative energy deficiency in sport (RED-S). British Journal of Sports Medicine, 48(7), 491–497. DOI: 10.1136/bjsports-2014-093502.
132. Mountjoy, M., Sundgot-Borgen, J. K., Burke, L. M., et al. (2018). IOC consensus statement on relative energy deficiency in sport (RED-S): 2018 update. British Journal of Sports Medicine, 52(11), 687–697. DOI: 10.1136/bjsports-2018-099193.
133. Areta, J. L., Taylor, H. L., & Koehler, K. (2021). Low energy availability: history, definition and evidence of its endocrine, metabolic and physiological effects in prospective studies in females and males. European Journal of Applied Physiology, 121(1), 1–21. DOI: 10.1007/s00421-020-04516-0.
134. Burke, L. M., Lundy, B., Fahrenholtz, I. L., & Melin, A. K. (2018). Pitfalls of conducting and interpreting estimates of energy availability in free-living athletes. International Journal of Sport Nutrition and Exercise Metabolism, 28(4), 350–363. DOI: 10.1123/ijsnem.2018-0142.
135. Joy, E. A., De Souza, M. J., Nattiv, A., et al. (2014). 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad. Current Sports Medicine Reports, 13(4), 219–232. DOI: 10.1249/JSR.0000000000000077.
136. Williams, N. I., Leidy, H. J., Hill, B. R., Lieberman, J. L., Legro, R. S., & De Souza, M. J. (2015). Magnitude of daily energy deficit predicts frequency but not severity of menstrual disturbances associated with exercise and caloric restriction. American Journal of Physiology - Endocrinology and Metabolism, 308(1), E29–E39. DOI: 10.1152/ajpendo.00386.2013.
137. Booth, F. W., Chakravarthy, M. V., & Spangenburg, E. E. (2002). Exercise and gene expression: physiological regulation of the human genome through physical activity. Journal of Physiology, 543(2), 399–411. DOI: 10.1113/jphysiol.2002.019265.
138. Joyner, M. J., & Coyle, E. F. (2008). Endurance exercise performance: the physiology of champions. Journal of Physiology, 586(1), 35–44. DOI: 10.1113/jphysiol.2007.143834.
139. Bouchard, C., Sarzynski, M. A., Rice, T. K., et al. (2011). Genomic predictors of the maximal O₂ uptake response to standardized exercise training programs. Journal of Applied Physiology, 110(5), 1160–1170. DOI: 10.1152/japplphysiol.00973.2010.
140. Lavie, C. J., Ozemek, C., Carbone, S., Katzmarzyk, P. T., & Blair, S. N. (2019). Sedentary behavior, exercise, and cardiovascular health. Circulation Research, 124(5), 799–815. DOI: 10.1161/CIRCRESAHA.118.312669.
141. Faigenbaum, A. D., Lloyd, R. S., MacDonald, J., & Myer, G. D. (2016). Citius, Altius, Fortius: beneficial effects of resistance training for young athletes — narrative review. British Journal of Sports Medicine, 50(1), 3–7. DOI: 10.1136/bjsports-2015-094621.
142. Garatachea, N., Pareja-Galeano, H., Sanchis-Gomar, F., et al. (2015). Exercise attenuates the major hallmarks of aging. Rejuvenation Research, 18(1), 57–89. DOI: 10.1089/rej.2014.1623.
143. Cartee, G. D., Hepple, R. T., Bamman, M. M., & Zierath, J. R. (2016). Exercise promotes healthy aging of skeletal muscle. Cell Metabolism, 23(6), 1034–1047. DOI: 10.1016/j.cmet.2016.05.007.
144. Pillon, N. J., Gabriel, B. M., Dollet, L., et al. (2020). Transcriptomic profiling of skeletal muscle adaptations to exercise and inactivity. Nature Communications, 11, 470. DOI: 10.1038/s41467-019-13869-w.
145. Holloszy, J. O., & Coyle, E. F. (1984). Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. Journal of Applied Physiology, 56(4), 831–838. DOI: 10.1152/jappl.1984.56.4.831.
146. Hawley, J. A., Joyner, M. J., & Green, D. J. (2021). Mimicking exercise: what matters most and where to next? Journal of Physiology, 599(3), 791–802. DOI: 10.1113/JP278761.
147. Bahr, R., & Holme, I. (2003). Risk factors for sports injuries — a methodological approach. British Journal of Sports Medicine, 37(5), 384–392. DOI: 10.1136/bjsm.37.5.384.
148. Khan, K. M., Thompson, A. M., Blair, S. N., et al. (2012). Sport and exercise as contributors to the health of nations. Lancet, 380(9836), 59–64. DOI: 10.1016/S0140-6736(12)60865-4.
149. Burr, J. F., Drury, C. T., Phillips, A. A., Ivey, A., Ku, J., & Warburton, D. E. R. (2014). Long-term ultra-marathon running and biomarkers for cardiovascular disease. Clinical Journal of Sport Medicine, 24(1), 62–67. DOI: 10.1097/JSM.0b013e3182a5106e.
150. Eijsvogels, T. M. H., Molossi, S., Lee, D., Emery, M. S., & Thompson, P. D. (2016). Exercise at the extremes: the amount of exercise to reduce cardiovascular events. Journal of the American College of Cardiology, 67(3), 316–329. DOI: 10.1016/j.jacc.2015.11.034.